Document:

Exhibit 10.5

 

Pursuant
to Item 601(B)(10) of Regulation S-K, certain portions of this exhibit have been redacted and, where applicable, have been marked
“[***],” such redactions are immaterial and would be competitively harmful if publicly disclosed.

 

 

 

RESEARCH AND LICENCE AGREEMENT

 

between

 

YEDA RESEARCH AND

DEVELOPMENT COMPANY LIMITED

 

and

 

MBCURE LTD.

 

 

 

     

     

    

 

TABLE OF CONTENTS

 

	Clause	 	Description	 	Page
	 	 	 	 	 
	1.	 	Preamble, Appendices and Interpretation	 	3
	 	 	 	 	 
	2.	 	Performance Of The Research	 	17
	 	 	 	 	 
	3.	 	Funding The Research	 	20
	 	 	 	 	 
	4.	 	Records and Reporting By Yeda	 	20
	 	 	 	 	 
	5.	 	Title	 	21
	 	 	 	 	 
	6.	 	Patents; Patent Infringements	 	22
	 	 	 	 	 
	7.	 	Licence	 	28
	 	 	 	 	 
	8.	 	Development and Commercialisation	 	34
	 	 	 	 	 
	9.	 	Royalties	 	36
	 	 	 	 	 
	10.	 	Confidentiality	 	42
	 	 	 	 	 
	11.	 	No Assignment	 	44
	 	 	 	 	 
	12.	 	Exclusion of Liability and Indemnification	 	45
	 	 	 	 	 
	13.	 	Term and Termination	 	46
	 	 	 	 	 
	14.	 	Notices	 	53
	 	 	 	 	 
	15.	 	Value Added Tax	 	53
	 	 	 	 	 
	16.	 	Governing law and jurisdiction	 	54
	 	 	 	 	 
	17.	 	Miscellaneous	 	54

 

    (i)

     

    

 

Execution Version

 

RESEARCH AND LICENCE AGREEMENT

 

Between

 

YEDA RESEARCH AND DEVELOPMENT COMPANY
LIMITED

 

a company duly registered under the
laws of Israel of P O Box 95, Rehovot 76100, Israel

 

(hereinafter, “Yeda”)

 

and

 

MBCURE LTD.

 

a company duly registered under the
laws of Israel with company number 51-522055-6, having its principal place of business at 2 Ilan Ramon Street, Science Part, Ness
Ziona, 7403635, Israel

 

(hereinafter, “the Company”)

 

		preamble:	

 

	WHEREAS:	(A)	in the course of research conducted at the Weizmann Institute of Science (“the Institute”), under the supervision of Dr. Eran Elinav of Department of Immunology and Professor Rotem Sorek of the Department of Molecular Genetics (“the Scientists”), the Scientists together with other scientists of the Institute (all of the aforementioned persons collectively “the Inventors”) created and/or generated the know-how and/or materials and other information described in Appendix A hereto, using the Institute’s state of the art preclinical germ-free mouse facility, anaerobic facility, robotic facility for high throughput phage discovery and sequencing facility (“the Existing Know-How”); and

 

     

     

    

 

	 	(B)	the Company is: (i) interested in the performance of further research at the Institute under the supervision of the Scientists in the field of the Technology (as hereinafter defined), as specified in the Research Program (as hereinafter defined) (“the Research”); and (ii) willing, subject to and in accordance with the terms and conditions of this Agreement, to finance the performance of the Research in accordance with the Research Budget (as hereinafter defined); and
	 	 	 
	 	(C)	Yeda is willing, subject to and in accordance with the terms and conditions of this Agreement, to procure the performance of the Research at the Institute as aforesaid; and
	 	 	 
	 	(D)	by operation of Israeli law and/or under the terms of employment of the Inventors at the Institute and pursuant to an agreement between the Institute, Yeda and the Inventors, all right, title and interest of the Institute and the Inventors in and to the Know How and in and to the Initial Research Results and the Subsequent Results (all as hereinafter defined) vests and shall vest in Yeda; and
	 	 	 
	 	(E)	it is contemplated that following the commencement of the Research, there will be collaborative activity between the Inventors and the Company, for example by way of the provision by the Inventors of phages for validation by the Company; 
	 	 	 
	 	(F)	subject to and in accordance with the terms of this Agreement, the Company wishes to receive, and Yeda is willing to grant to the Company, the License in respect of the Licensed Information and Yeda’s rights in the Subsequent Results and under the Yeda Patents and Yeda’s rights in the Joint Patents (all as hereinafter defined), all subject to and in accordance with the terms and conditions of this Agreement; and

 

    - 2 -

     

    

 

	 	(G)	the Company warrants and represents that: (i) the Company was duly incorporated on 3 March 2015, its initial purpose being to implement an “incubator project” (as such term is defined in section 2.13 of Directive No. 8.22 of the Director-General of the Ministry of the Economy (“the Ministry”)) (“the Incubators Directive”) for the development and commercialisation of Products (“the Project”); (ii) the Project has been accepted by the biotechnological incubator FutuRX Limited (“FutuRx”); (iii) pursuant to a written authorisation (“the Letter of Approval”) dated 29 December 2014 as amended on 3 March 2015, the Project was approved by the “biotechnology incubators committee” at the Ministry (as defined in section 3 of the Incubators Directive (“the Incubators Committee”) on the terms set out therein for receipt of government support (including grants) and incubator services pursuant to the Incubators Directive and applicable law; and (iv) FutuRx has undertaken to invest the amount of [***] in the Company over the course of a [***] period in excess of the investment therein required of FutuRx as an incubator pursuant to law and regulations.

 

NOW THEREFORE IT IS AGREED BETWEEN THE
PARTIES HERETO AS FOLLOWS:

 

		1.	Preamble, Appendices and Interpretation

 

		1.1.	The Preamble and Appendices hereto form an integral part of this Agreement.

 

		1.2.	In this Agreement the terms below shall bear the meanings assigned to them below, unless the context
shall indicate a contrary intention:

 

	 	1.2.1.	“Affiliated Entity”	-	shall mean, with respect to any body, any company, corporation,
    other entity or person (hereinafter, collectively, “entity”), which directly or indirectly, is controlled
    by, or controls, or is under common control with, such body. For the purposes of this definition, “control”
    shall mean the ability, directly or indirectly, to direct the activities of the relevant entity (save for an ability flowing
    solely from the fulfilment of the office of director or another office) and shall include, the holding, directly or
    indirectly, of more than [***] of the issued share capital or of the voting power of the relevant entity or the holding,
    directly or indirectly, of a right to appoint more than [***] of the directors of such entity or of a right to appoint the
    chief executive officer of such entity;

 

    - 3 -

     

    

 

	 	1.2.2.	“Companion Diagnostic Kits”	-	shall mean with respect to any Product or Other Product, a Diagnostic Kit as referred to in  clause 1.2.17 below used in the development and/or application of such Product or Other Product;
	 	 	 	 	 
	 	1.2.3.	“Company Products”	-	shall mean Group 1 Company Products and Group 2 Company Products;
	 	 	 	 	 
	 	1.2.4.	“Company Results”	-	shall mean all and any inventions, products, materials, compounds, compositions, substances, methods, processes, techniques, know-how, data, information, discoveries and other results of whatsoever nature covering or constituting Group 2 Company Products Discovered or occurring in the course of, or arising from, the performance of activities of any nature by the Company outside the facilities of the Institute which are not joint or collaborative with the Scientists (including via consultancy or other agreements or arrangements), WIS or Yeda and to which the Scientists have not contributed in any way;
	 	 	 	 	 
	 	1.2.5.	“Development Program”	-	shall mean, with respect to any Product or Products, a development program specifying the activities and timetable necessary to develop such Products to commercialisation;
	 	 	 	 	 
	 	1.2.6.	“Discovered”	-	shall mean, with regard to a Group 2 Product, the time when such Product or any part thereof was first identified, whether by way of a claim in a patent application or in any written record; 

 

    - 4 -

     

    

 

	 	1.2.7.	“Distributor”	 	shall mean an independent third party not affiliated with either the Company or any Sublicensee with whom there is a bona fide distribution, reseller or similar agreement pursuant to which such third party does not have any rights under the Licensed Information, the Subsequent Results or the Patents and purchases Products or Other Products from the Company or a Sublicensee or from another Distributor in consideration for the purchase price therefor only (and no other consideration), solely for resale and/or distribution in the same form (meaning without any change and/or reconfiguration thereof or incorporation thereof into any other product) to another Distributor or to end-users, for monetary consideration only;
	 	 	 	 	 
	 	1.2.8.	“Exchange Rate”	-	shall mean, with respect to any amount to be calculated, or which is paid or received in a currency other than US Dollars, the average of the selling and buying exchange rates of such currency (in respect of cheques and remittances) and the US Dollar prevailing at Bank Hapoalim B.M. at the end of business on the date of calculation, payment or receipt, as the case may be;
	 	 	 	 	 
	 	1.2.9.	“First Commercial Sale”	-	shall mean, with respect to any Product in any country, the first commercial sale of such Product in such country after  new drug approval by the U.S. Food and Drug Administration (“the FDA”), or, in the case of any member state of the European Union, the European Medicines Agency (“the EMA”) or any other national medicinal agency marketing approval or equivalent approval in such country has been obtained for such Product;

 

    - 5 -

     

    

 

	 	1.2.10.	“Group 1 Company Products”	-	shall mean drug products (other than WIS Products) for the treatment of any indication based on the drug product candidates detailed in the Research Program, containing bacteriophages for use as antibacterial agents where such bacteriophages were specifically developed under the Research Plan; 
	 	 	 	 	 
	 	1.2.11.	“Group 2 Company Products”	-	shall mean drug products (other than WIS Products or Group 1 Company Products) for the treatment of any indication which contain bacteriophages for use as microbiome or Microbiota antibacterial agents or modulators, which products were developed or discovered by the Company during a period of [***] commencing on the date hereof; however, if at the expiration of such [***] period there are fewer than [***] Company Products which are drugs, such period will be extended until there are [***] Company Products in total which are drugs;
	 	 	 	 	 
	 	1.2.12.	“Incubator Period”	-	shall mean the period during which the Company receives services from FuturRx, as approved by the OCS from time to time, being approximately [***] in total as from the commencement date indicated in the Letter of Approval; 
	 	 	 	 	 
	 	1.2.13.	“Initial Development Program”	-	shall mean a program detailing the research and development activities which the Company aims to accomplish during the Incubator Period, as submitted to the Incubators Committee and amended on an annual basis during the Incubator Period, and which will include all activities to be funded by the Company during the Incubator Period;

 

    - 6 -

     

    

 

	 	1.2.14.	“Initial Research Results”	-	shall mean all and any inventions, products, materials (which may include bacteria and phages), compounds, compositions, substances, methods, processes, techniques, know-how, data, information, discoveries and other results of whatsoever nature discovered or occurring in the course of, or arising from, the performance of:
	 	 	 	 	 
	 	 	 	 	
        (i)    the
        Research; or

         

        (ii)    activities
        of any nature which are joint or collaborative between the Inventors (including via consultancy or other agreements or arrangements)
        and the Company,

	 	 	 	 	 
	 	 	 	 	in either case related to or underlying WIS Products (or to any Companion Diagnostic Kits to such WIS Products) as described in clause 1.2.30 below;
	 	 	 	 	 
	 	1.2.15.	“Investment”	-	shall mean any amount received by or invested in the Company  in return for the issuance of either equity or debt, and any amounts received by the Company from the Incubators Committee or otherwise from the Office of the Chief Scientist of the Ministry of Economics (the “OCS”);

 

    - 7 -

     

    

 

	 	1.2.16.	“Know-How”	-	shall mean (i) the Existing Know-How; (ii) any non-patented information disclosed to the Company hereunder and which is not in the public domain, including information obtained during the Research (other than the Initial Research Results); (iii) proprietary materials emanating from the Research or part of the Existing Know How (which may include bacteria and phages); and (iv) any future developments, improvements or inventions by either of the Scientists of or related to the Technology, provided that during the calendar year in which the creation thereof occurs the Company is providing funding for research related to the Technology at the laboratories of the Scientists at the Institute in the sum of at least [***] per calendar year per each of the two laboratories (above and beyond any amounts directly required for the purchase of mice);
	 	 	 	 	 
	 	1.2.17.	“Licence”	-	shall mean an exclusive worldwide licence under:
	 	 	 	 	 
	 	 	 	 	
        (i)     the
        Licensed Information;

         

        (ii)    Yeda’s
        rights in the Subsequent Results; and

         

        (iii)   Yeda’s
        rights in the Yeda Patents and the Joint Patents;

 

    - 8 -

     

    

 

	 	 	 	 	for (a) the development, testing manufacture, production, and sale of Products, (b) for the development, testing manufacture, production, and sale of drug products, other than Products, for the treatment of any indication which contain bacteriophages for use as microbiome or Microbiota antibacterial agents or modulators (“Other Products”); and (c) for the use of bacteriophages in kits to be used  only for diagnosis in the development of any Product or Other Product or for the purpose of diagnosis in applying any Product or Other Product (“Diagnostic Kits”), but for the avoidance of doubt not for sale by the Company unless such Diagnostic Kits are sold with  labelling showing that such Diagnostic Kits may be used only in order to determine which Product or Other Product, if any, may appropriately be used (and not for any other form of diagnosis, including with respect to products, other than a Product or Other Product), all the above in this clause 1.2.17, subject to the provisions of clause 7.1 below and the other terms and conditions of this Agreement.  Notwithstanding anything to contrary in this Agreement, the Licence shall not include the use of bacteriophages to treat against free-living bacteria (such as for environmental treatment) outside the human organism, but there shall be no restriction on the Company developing such treatments independently of the Institute without any use of the Licensed Information or the Subsequent Results; 
	 	 	 	 	 
	 	1.2.18.	“Licensed Information”	-	shall mean: (i) the Know-How; and (ii) the Initial Research Results.  Specific genes or proteins for targeted anti-bacterial treatment which are identified and/or developed by any of the Scientists shall not be regarded as Technology and shall not be included in the Licensed Information; 
	 	 	 	 	 
	 	1.2.19.	“Microbiota”	-	shall mean the community of commensal, symbiotic, and pathogenic microorganisms found within the human body; 
	 	 	 	 	 
	 	1.2.20.	“Net Sales”	-	shall mean:
	 	 	 	 	 
	 	 	 	 	(i)     the total amount invoiced by the Company or any Affiliated Entity thereof and the total amount invoiced by each Sublicensee in connection with the sale of WIS Products (including any Companion Diagnostic Kits of any WIS Products, whether sold together with or separately from any WIS Products); and

 

    - 9 -

     

    

 

	 	 	 	 	(ii)    the total amount invoiced by the Company or any Affiliated Entity thereof in connection with the sale of Company Products (including any Companion Diagnostic Kits of any Company Products, whether sold together with or separately from any Company Products);
	 	 	 	 	 
	 	 	 	 	(for the avoidance of doubt, whether such sales are made before or after the First Commercial Sale of any Product in any country); in all cases after deduction of:
	 	 	 	 	 
	 	 	 	 	
        (i)     sales
        taxes (including value added taxes) to the extent applicable to such sale and included in the invoice in respect of such sale;

         

        (ii)   freight
        and insurance charges to the extent such items are separately itemised on invoices;

         

        (iii)   credits
        or allowances, if any, actually granted on account of price adjustments, recalls, rejections or returns of Products previously
        sold;

         

        (iv)   bad
        debts (as determined in accordance with relevant GAAP rules) deriving from Net Sales in respect of which royalties were paid by
        the Company hereunder;

 

    - 10 -

     

    

 

	 	 	 	 	provided that:
	 	 	 	 	 
	 	 	 	 	
        (a)    with
        respect to sales which are not at arms-length and/or are not in the ordinary course of business and/or are not according to then
        current market conditions for such a sale, the term “Net Sales” shall mean the total amount that would have
        been due in an arms-length sale made in the ordinary course of business and according to the then current market conditions for
        such sale or, in the absence of such current market conditions, according to market conditions for sale of products similar to
        the Products (or Companion Diagnostic Kits, as applicable); and

         

        (b)    with
        respect to sales by the Company of Products (or Companion Diagnostic Kits, as applicable) and/or sales by a Sublicensee of WIS
        Products (or Companion Diagnostic Kits, as applicable), as applicable, to any Affiliated Entity of the Company or of such Sublicensee,
        as the case may be, the term, “Net Sales” shall mean the higher of: (A) ”Net Sales”, as defined
        in paragraph (a) above; and (B) the total amount invoiced by such Affiliated Entity on resale to an independent third
        party purchaser after the deductions specified in subparagraphs (i) and (ii) above, to the extent applicable;

	 	 	 	 	 
	 	1.2.21.	“Patents”	-	shall mean: 
	 	 	 	 	 
	 	 	 	 	
        (i)     all
        patent applications or applications for certificates of invention covering portions of the Licensed Information and all patents
        or certificates of invention which may be granted thereon (“the Yeda Patents”); and

         

        (ii)    all
        patent applications or applications for certificates of invention (if any) covering all or some of the Subsequent Results and all
        patents or certificates of invention which may be granted thereon (“the Joint Patents”);

 

    - 11 -

     

    

 

	 	 	 	 	in each case as well as all continuations, continuations-in-part, patents of addition, divisions, renewals, reissues and extensions (including any patent term extension) of any of the aforegoing patents, but excluding: (a) patents that have been invalidated or cancelled pursuant to the final (i.e., unappealed or unappealable) judgment of a competent court; and (b) patent applications that have been withdrawn or have expired, in each case such exclusion to be effective only from the date of such invalidation, cancellation, withdrawal or expiry, as the case may be. 
	 	 	 	 	 
	 	 	 	 	For the purposes of this Agreement, the term “Patent” shall also mean Supplementary Protection Certificate (within the meaning of such term under Council Regulation (EU) No. 1768/92) or any application therefor or any other similar statutory protection (by way of patent extension or otherwise) or application therefor in any jurisdiction;
	 	 	 	 	 
	 	1.2.22.	“Products”	-	shall mean WIS Products and Company Products;
	 	 	 	 	 
	 	1.2.23.	“Research Budget”	-	shall mean the agreed research budget for the first [***] of the Research Period attached hereto and marked Appendix B, and any further research budget as may be agreed by the parties in writing from time to time;

 

    - 12 -

     

    

 

	 	1.2.24.	“Research Period”	-	shall mean the [***] period commencing on May 1, 2015, as such period may be extended from time to time by agreement in writing of the parties;
	 	 	 	 	 
	 	1.2.25.	“Research Program”	-	shall mean the research program agreed upon for the first [***] of the Research Period attached hereto and marked Appendix C, and any further research program as maybe agreed by the parties in writing from time to time; 
	 	1.2.26.	“Subcontract” and “Subcontractor”	-	shall mean a bona fide written subcontracting agreement pursuant to which a contractor is engaged on a pure work order basis for the sole purpose of manufacturing or development of a product (or part thereof) on the Company’s behalf, for monetary consideration only;
	 	 	 	 	 
	 	1.2.27.	“Sublicence” and “Sublicensee”	-	“Sublicence” shall mean any right granted, licence given, or agreement entered into, by the Company to or with any other person or entity, permitting any use of the Licensed Information and/or the Subsequent Results and/or the Yeda Patents and/or the Joint Patents (or any part thereof), including for the development and/or testing and/or manufacture and/or production and/or marketing and/or sale of Products (whether or not such grant of rights, licence given or agreement entered into is described as a sublicence or as an agreement with respect to the development and/or testing and/or manufacture and/or production and/or marketing and/or sale of Products or otherwise) and/or use of the Company Results for the development and/or testing and/or manufacture and/or production and/or marketing and/or sale of Group 2 Company Products and the term “Sublicensee” shall be construed accordingly.  For the purposes of this Agreement, “Sublicensee” shall not include a Subcontractor or a Distributor, as defined herein;

 

    - 13 -

     

    

 

	 	1.2.28.	“Sublicensing Receipts”	-	shall mean consideration, whether monetary or otherwise, including fees and lump sum payments, received (for the avoidance of doubt, whether received before or after the First Commercial Sale in any country) by the Company for or from the grant of Sublicences and/or pursuant thereto, or in connection with the grant of an option for a Sublicence (where such option is in return for consideration) (for the further avoidance of doubt, including amounts received by the Company which constitute royalties based on sales of Company Products by Sublicensees), except for:
	 	 	 	 	 
	 	 	 	 	
        (i)     amounts
        received by the Company which constitute royalties based on sales of WIS Products by Sublicensees in respect of which royalties
        are payable to Yeda hereunder;

         

        (ii)    amounts
        received by the Company from:

	 	 	 	 	 
	 	 	 	 	(1)    a Sublicensee to cover direct costs of Product-related research or development activities to be performed by the Company for such Sublicensee after the date of signature of the relevant Sublicence (or, as the case may be, option for a Sublicence) or

 

    - 14 -

     

    

 

	 	 	 	 	(2)    governmental or philanthropic sources, including the Incubators Committee, for Product-related research or development activities
	 	 	 	 	 
	 	 	 	 	and actually expended by the Company (as evidenced by invoices, receipts or other appropriate documentation), provided that:
	 	 	 	 	 
	 	 	 	 	
        (a)    any
        such amounts constitute research and/or development funding only and not payment for Products nor any other type of grant or benefit,

         

        (b)    such
        research and/or development activities are performed pursuant to a defined research and development program and research and development
        budget agreed with the relevant Sublicensee, a copy of which is provided to Yeda; and

         

        (c)    the
        Company submits to Yeda a written expense report, confirmed by the Company’s independent accountant or chief financial officer,
        setting out the time and materials utilised, and reasonable overhead costs and other expenses actually incurred by the Company
        in the conduct of the said research and development activities, which report demonstrates that such amounts have actually been
        expended by the Company in the conduct of such research and/or development activities in accordance with such work program and
        budget and at the times set out therein,

         

        it being agreed, for
        the avoidance of doubt, that any amounts received by the Company as aforesaid, but not expended as set out in this sub-clause (ii),
        shall be deemed to be Sublicensing Receipts;

         

        (iii)   amounts
        received by the Company which are used by the Company for the purpose of the payment of costs and fees incurred in the preparation,
        filing, prosecution and the like of patent applications filed in accordance herewith and the maintenance of any patents granted
        thereon; and

         

        (iv)   investments
        in the equity or debt of the Company to the extent such investments are at fair value (amounts above fair value will be deemed
        Sublicensing Receipts);

	 	 	 	 	 
	 	1.2.29.	“Subsequent Results”	-	shall mean all and any inventions, products, materials (which may include bacteria and phages), compounds, compositions, substances, methods, processes, techniques, know-how, data, information, discoveries and other results of whatsoever nature discovered or occurring in the course of, or arising from, the performance of 
	 	 	 	 	 
	 	 	 	 	(i)    the Research; or

 

    - 15 -

     

    

 

	 	 	 	 	(ii)   activities of any nature which are joint or collaborative between the Inventors (including via consultancy or other agreements or arrangements) and the Company,
	 	 	 	 	 
	 	 	 	 	in either case related to or underlying Group 1 Company Products (including any Companion Diagnostic Kits of any Group 1 Company Products);
	 	 	 	 	 
	 	1.2.30.	“Technology”	-	shall mean a technology for identification and/or development of bacteriophages as candidates for targeted anti-bacterial treatment through human-body associated microbiome or Microbiota modulation;
	 	 	 	 	 
	 	1.2.31.	“WIS Products”	-	shall mean drug products based on the first two drug product candidates, as detailed in the Research Program (being in respect of colorectal cancer and inflammatory bowel disease), which are submitted to the Incubators Committee by the Company within the framework of the Project, containing bacteriophages for use as antibacterial agents where such bacteriophages were initially identified in the Licensed Information.
	 	 	 	 	 
	 	1.2.32.	the terms: “Yeda”, “the Company”, “the Institute”, “the Scientists”, “the Inventors”, “the Existing Know-How”, “the Research”, “the Ministry”, “the Incubators Directive”, “the Project”, “FutuRx”, “the Letter of Approval” and “the Incubators Committee”	-	shall bear the definitions assigned to them respectively in the heading or the preamble hereto, as the case may be.

 

    - 16 -

     

    

 

		1.3.	In this Agreement:

 

		1.3.1.	words importing the singular shall include the plural and vice-versa and words importing
any gender shall include all other genders and references to persons shall include partnerships, corporations and unincorporated
associations;

 

		1.3.2.	any reference in this Agreement to the term “patent” shall also include any re-issues,
divisions, continuations or extensions thereof (including measures having equivalent effect);

 

		1.3.3.	any reference in this Agreement to the term “patent applications” shall include any
provisional patent applications, PCT, national or regional patent applications, applications for continuations, continuations-in-part,
divisions, patents of addition or renewals, as well as any other applications or filings for similar statutory protection;

 

		1.3.4.	any reference in this Agreement to the term “sale” shall include the sale, lease, rental
or other disposal of any Product; and

 

		1.3.5.	“including” and “includes” means including, without limiting
the generality of any description preceding such terms.

 

		2.	PERFORMANCE OF THE RESEARCH

 

		2.1.	In consideration of the sums to be paid by the Company to Yeda pursuant to clause 3 below
and, subject to the execution of such payments, Yeda undertakes, subject to clause 2.2 below, to procure the performance of
the Research at the Institute under the supervision of the Scientists during the Research Period. By written agreement of the parties,
the Research Period may be extended by such period and upon such terms and conditions as the parties shall so agree.

 

    - 17 -

     

    

 

		2.2.	If either or both of the Scientists shall cease to be available for the supervision of the performance
of the Research, such cessation shall not constitute a breach of this Agreement by Yeda. In the event that either or both of the
Scientists shall cease to be available as aforesaid, Yeda shall use its reasonable efforts to find from amongst the scientists
of the Institute replacement scientists acceptable to the Company (such acceptance to be in writing, and not to be unreasonably
withheld), but no undertaking to find such replacements is given by Yeda. If no such acceptable replacement scientists can be found
within [***] of either or both of the Scientists becoming unavailable as aforesaid, then the Company shall be entitled, by written
notice to Yeda, to terminate the Research Period, in which event the Research Period and the performance of Research hereunder
shall cease at the end of the calendar quarter during which such written notice was given. During the period between the date of
such notice by the Company and the cessation of the Research, Yeda shall make reasonable efforts to procure the minimising of further
Research expenses (save with respect to any obligations already undertaken which cannot be cancelled or reduced) and in co-operation
with the Company shall make reasonable efforts to procure that experiments covered by the Research Budget applicable until the
date of such cessation are completed. In the event of such termination, Yeda shall be released from any obligation to procure the
performance of the Research during the period after such termination, and the Company shall be released from any obligation to
finance the Research in respect of the period commencing after such termination, but without affecting the Licence and all the
other terms and conditions of this Agreement which shall remain in full force and effect (save for those relating to the performance
and financing of the Research). In the event of such termination, Yeda shall make reasonable efforts to provide to the Company
all data including any raw data generated in the course of the Research.

 

		2.3.	It is agreed that if the performance of the Research shall involve the conduct of experiments on
and/or using animals, the performance of the Research and the Research Program shall be subject to the Israeli Anti-Cruelty Law,
1994 and to the approval of, and any modifications requested by, the Institutional Animal Care and Use Committee and the Safety
Committee of the Institute, in order to ensure compliance with the above law. It is agreed that, in view of the fact that the performance
of the Research may involve the conduct of experiments using human material (such as cells, blood, tissue, DNA, RNA, lysates, or
body fluids) the performance of the Research and the Research Program shall be subject to the approval of, and any modifications
requested by the Safety Committee of the Institute and the Institutional Review Board for Human Experimentation.

 

    - 18 -

     

    

 

		2.4.	It is further agreed that if the performance of the Research shall involve generators of biological
diseases, as defined in the Regulation of Research into Generators of Biological Diseases Law, 2008 (“the Biological Research
Law”), the performance of the Research and the Research Program shall be subject to the provisions of the Biological
Research Law and to the obtaining of all the necessary approvals required thereunder. In the event that if, during the performance
of Research for which initially no approval was required pursuant to the Biological Research Law, there shall be discovered findings
which may increase the aggressiveness, transferability or host range of biological diseases, which findings require the suspension
of the Research until the approvals required pursuant to the Biological Research Law are obtained, any such suspension of the Research
shall not constitute a breach of this Agreement by Yeda.

 

		2.5.	For the avoidance of doubt, it is agreed that nothing in this Agreement shall constitute a representation
or warranty by Yeda, express or implied, (i) that any patent applications relating to the Licensed Information or the Subsequent
Results or any portion thereof respectively will be granted; or (ii) that the patents obtained on any of the said patent applications
are or will be valid or will afford proper protection; or (iii) that any portion of the Licensed Information or the Subsequent
Results is or will be commercially exploitable or of any other value; or (iv) that the exploitation of the Patents, the Licensed
Information or the Subsequent Results will not infringe the rights of any third party, save that Yeda confirms that as of the date
hereof it is not aware of any allegations by any third party as to the infringement by the Licensed Information of any patent or
as to the misappropriation of the Licensed Information or as to the right of Yeda to license any of the foregoing. Yeda furthermore
makes no warranties and representations, express or implied, whatsoever as to the Research, the Initial Research Results, the Subsequent
Results or the Licensed Information.

 

    - 19 -

     

    

 

		3.	FUNDING THE RESEARCH

 

		3.1.	The Company undertakes to pay to Yeda the total amount (in US Dollars) of the Research Budget,
as follows: during each year of the Research Period, [***] of the proportionate amount due in respect of such year in [***], payable
in advance at the beginning of each [***] period during such year, the first such payment to be made on the [***] of such year
(which in respect of the first year of the Research Period is the date of Company activation as indicated in the Letter of Approval),
with the remaining [***] of such annual amount to be paid immediately following the delivery to the Company of the twelve-monthly
research report and transfer of the reagents both as referred to in clause 4.1 below due at the end of each year of the Research
Period.

 

		3.2.	An invoice in respect of an instalment paid as aforesaid shall be issued by Yeda promptly after
the receipt by Yeda of such instalment. All payments of the Research Budget shall be made by direct wire transfer to Yeda’s
bank account, the details of which are set out in clause 19.8 below.

 

		3.3.	For the avoidance of doubt, nothing contained in this Agreement shall prevent Yeda and/or the Institute
from obtaining further finance for the Research from other entities, provided that such other entities are not granted any rights
in respect of the Research or the Licensed Information which prejudice any rights granted to the Company under the Licence.

 

		4.	RECORDS AND REPORTING BY YEDA

 

		4.1.	Yeda shall procure that the Scientists (and any persons participating in the performance of the
Research at the Institute under the supervision of the Scientists) will prepare and keep in accordance with practice at the Institute
records of all Research activities and results.  The Company will be entitled to have through Yeda reasonable access to such
records, following written request from the Company to Yeda.

 

		4.2.	Yeda will procure the preparation by the Scientists of, and shall submit to the Company: (i) an
interim written report on the progress of the Research in each [***] period during the Research Period, within [***] of the end
of each such [***] period, and of a written report summarising the results of the Research within [***] of the end of the Research
Period; and (ii) reports of any significant findings in the Research promptly upon such findings being made.

 

    - 20 -

     

    

 

		4.3.	Yeda shall submit to the Company, with respect to each [***] period of the Research Period, a financial
report setting forth the monies received and expended in connection with the Research during such [***] period. Each report as
aforesaid shall be submitted to the Company not later than [***] after the end of the period covered by such report.

 

		5.	TITLE

 

		5.1.	Subject only to the Licence:

 

		5.1.1.	all right, title and interest in and to the Existing Know-How and the Yeda Patents covering all
or part of the Existing Know How, vest and shall vest in Yeda;

 

		5.1.2.	all right, title and interest in and to the Know-How (other than the Existing Know-How), the Initial
Research Results, the Subsequent Results, the Yeda Patents (other than the Yeda Patents covering all or part of the Existing Know
How) and the Joint Patents, shall vest jointly in Yeda and the Company in equal shares.

 

		5.2.	For the avoidance of doubt, all right, title and interest in and to the Company Results and all
right, title and interest in and to all other data, results, information, know-how, and any new invention generated by the Company
in connection with its activities hereunder not falling within clause 5.1.1. or 5.1.2 above (as between the Company and Yeda) vest
and shall vest in the Company.

 

		5.3.	In the event of the termination of this Agreement for any reason whatsoever, any interest which
the Company shall have in the Initial Research Results and in those Yeda Patents referred to in clause 5.1.2 shall be automatically
assigned to Yeda. To secure such assignment as aforesaid, concurrently with the execution of this Agreement, the Company shall
execute an irrevocable Power of Attorney in the form attached hereto as Appendix D, authorising the automatic assignment
of all rights of the Company in the Initial Research Results and such Yeda Patents to Yeda, upon Yeda’s written instructions,
which instructions Yeda may issue in the event of the termination of this Agreement for any reason whatsoever. Such Power of Attorney
shall be held in escrow by patent counsel chosen by the parties. It is understood and agreed that such patent counsel shall have
no discretion, shall release such Power of Attorney to Yeda upon notice from Yeda to such patent counsel confirming that this Agreement
has been terminated, and shall act upon Yeda’s instructions by virtue thereof, upon Yeda’s first demand. The Company
[***] shall execute any additional document and perform any acts as may be required to do so. Notwithstanding the foregoing, any
such transfer shall be subject, if required, to the consent of the Incubators Committee and/or to Yeda’s undertaking to comply
with and assume any regulatory obligations in respect thereof, including the payment of royalties to the OCS.

 

    - 21 -

     

    

 

		6.	Patents; Patent Infringements

 

		6.1.	

 

		6.1.1.	At the initiative of either party, the parties shall consult with one another regarding the filing
of patent applications in respect of any portion of the Licensed Information and/or the Subsequent Results, including the jurisdictions
in which such applications should be filed, the timing of the filing of such applications and the contents thereof. Following such
consultations, Yeda shall (subject to payment by the Company under clause 6.2 below) retain outside patent counsel approved by
the Licensee to prepare, file and prosecute patent applications in respect of any portion of the Licensed Information, and the
Company shall retain outside patent counsel to prepare, file and prosecute patent applications in respect of any portion of the
Subsequent Results, in each case in such jurisdiction or jurisdictions as shall be determined by the parties in consultation as
aforesaid. Each of Yeda and the Company (in the case of Yeda, subject to clause 6.3 below) shall also maintain at the applicable
patent office any patents granted as a result of any of the above patent applications made by them respectively as aforesaid. The
parties agree that their joint policy will be to seek comprehensive patent protection for all Licensed Information and Subsequent
Results licensed to the Company hereunder at least in the following countries: [***], unless, with respect to any country as aforesaid
and any patent application, all of the subject matter claims in such patent application are as a matter of law not patentable in
such country. The Company and Yeda shall co-operate fully in the preparation, filing, prosecution and maintenance of all such patent
applications and patents as aforesaid.

 

    - 22 -

     

    

 

		6.1.2.	Without derogating from the aforegoing, the Company shall [***] take all necessary steps in order
to obtain, or, at Yeda’s election in the case of patents covering any part of the Licensed Information, assist Yeda to obtain,
the extension of each patent referred to in this clause 6.1 above, or, in the case of a patent in any member state of the
European Union, a Supplementary Protection Certificate as referred to in clause 1.2.20 above (including, the preparation and
filing of applications for such extensions and Supplementary Protection Certificates), within the period prescribed therefor under
applicable law and, if applicable, take all necessary steps in order to obtain “Orphan Drug” status (within the meaning
of such term under the US Orphan Drug Act or under Council Regulation (EU) No. 141/2000, as the case may be), or paediatric
use approval, within the period prescribed therefor under applicable law. The Company shall notify Yeda promptly in writing and
shall provide a copy to Yeda of each marketing authorisation granted in respect of each Product in each country and, if applicable,
of “Orphan Drug” or paediatric use approval granted in respect of a Product and shall keep Yeda informed and shall
provide copies to Yeda of all documents regarding all applications, activities and/or proceedings regarding such extensions and/or
any Supplementary Protection Certificates and/or “Orphan Drug” or paediatric use approval, as aforesaid.

 

		6.1.3.	All applications to be filed in accordance with the provisions of clauses 6.1.1 and 6.1.2
above covering any part of the Existing Know-How shall be filed in the name of Yeda or, should the law of the relevant jurisdiction
so require, in the name of the relevant inventors and then assigned to Yeda. All applications to be filed in accordance with the
provisions of clauses 6.1.1 and 6.1.2 above covering any part of the Know-How (other than the Existing Know-How), the Initial
Research Results and the Subsequent Results shall be filed in the joint names of Yeda and the Company or, should the law of the
relevant jurisdiction so require, in the name of the relevant inventors and then assigned to Yeda and the Company in joint names.

 

    - 23 -

     

    

 

		6.2.	

 

		6.2.1.	The Company shall bear and pay all costs and fees incurred in the preparation, filing, prosecution
and the like of all patent applications filed in accordance with the provisions of clauses 6.1.1 and 6.1.2 above, and the
maintenance at the appropriate patent office and like of all patent applications referred to above, and all costs and fees incurred
in undertaking any activities referred to in clause 6.1.2 above.

 

		6.2.2.	Unless otherwise instructed by Yeda in writing, the Company shall, where applicable, pay directly
to Yeda’s relevant outside patent counsel amounts payable by the Company pursuant to this clause 6.2 above or otherwise
pursuant to this clause 6 above.

 

		6.3.	

 

		6.3.1.	Should the Company determine that a third party is infringing one or more of the Patents or misappropriating
all or some of the Licensed Information or the Subsequent Results, then the Company shall notify Yeda promptly in writing, giving
full particulars of such infringement or misappropriation. The Company shall within [***] of such notification (“Notification
Deadline”) indicate to Yeda in writing as to whether the Company wishes to sue for such infringement or misappropriation
(the Company not being obliged to sue for such infringement or misappropriation). In the event that the Company shall fail to give
any indication in writing to Yeda as aforesaid, the Company shall be deemed to have decided not to sue for such infringement or
misappropriation.

 

		6.3.2.	In the event that the Company shall notify Yeda that it wishes to sue for such infringement or
misappropriation, the Company shall, as part of such notification, advise Yeda of its proposed choice of legal counsel to represent
the Company in such suit. Yeda shall, within [***] of such notification, notify the Company in writing whether it approves such
proposed legal counsel (such approval not to be unreasonably withheld). In the event that Yeda shall fail to respond to the Company
during such [***] period, Yeda shall be deemed to have approved such legal counsel.

 

		6.3.3.	Yeda may elect, at its own initiative, to join as a party to such suit, or Yeda may consent (in
response to a request by the Company) to being named as a party to such suit (and will consent with regard to any jurisdiction
where this is required in order for suit to be brought). Yeda may elect to be represented in such suit by the Company’s choice
of legal counsel, or at any time during such suit, engage its own legal counsel therein.

 

    - 24 -

     

    

 

		6.3.4.	Any
consent by Yeda to being named as a party to such suit may be conditional upon, inter alia, the provision by the Company
of security, satisfactory to Yeda, for the payment of any expenses or costs or other liabilities incurred in connection with such
suit (including the fees and costs of Yeda’s legal counsel, and attorneys’ fees, costs or other sums awarded to the counterparty
in such suit) (such expenses or costs “Litigation Expenses”).

 

		6.3.5.	All
                                         Litigation Expenses in connection with any such suit where Yeda consents to be named
                                         as a party shall be borne by the Company, which shall indemnify Yeda against any such
                                         expenses or costs or other liabilities (without derogating from the provisions of clause 12
                                         below). Provided, however, that if Yeda shall have approved the Company’s choice of legal
                                         counsel in accordance with clause 6.3.2 above but shall have engaged its own legal
                                         counsel, Yeda shall bear the fees and costs of such legal counsel, unless such engagement
                                         shall be due to the perception of the joint legal counsel as aforesaid, whether at the
                                         commencement of such suit or thereafter, that there is or may be a conflict of interests
                                         between the Company and Yeda, or due to the Company’s legal counsel having declined
                                         to represent Yeda, in which case the Litigation Expenses shall be borne by the Company.
                                         Should Yeda elect to join such suit and choose its own legal counsel, then Yeda shall
                                         bear its own Litigation Expenses.

 

		6.3.6.	In
                                         the event that the Company: (a) shall not have notified Yeda of the Company’s intention
                                         to commence suit by the Notification Deadline; or (b) shall not have commenced such
                                         suit within [***] thereafter, then Yeda shall have the right (but not the obligation)
                                         to commence suit for such infringement [or misappropriation.

 

		6.4.	

 

		6.4.1.	Should
                                         the Company discover any allegation by a third party that, or be sued on the grounds
                                         that, the manufacture, use or sale of a Product by it or by a Sublicensee under any of
                                         the Patents infringes upon the patent rights of a third party, then the Company shall
                                         notify Yeda promptly in writing, giving full particulars thereof, and the Company shall,
                                         after first having consulted Yeda, be entitled to defend such suit, subject to clause 6.4.2
                                         below.

 

    - 25 -

     

    

 

		6.4.2.	If
                                         a suit as referred to in clause 6.4.1 above includes (or it is reasonable to assume
                                         that it will include) a Patent Challenge (as hereinafter defined), then the following
                                         provisions shall apply:

 

		6.4.2.1.	the
                                         Company shall, as part of such notification, advise Yeda of its proposed choice of legal
                                         counsel to represent the Company in such suit. Yeda shall, within [***] of such notification,
                                         notify the Company in writing whether it approves such proposed legal counsel (such approval
                                         not to be unreasonably withheld). In the event that Yeda shall fail to respond to the
                                         Company during such [***] period, Yeda shall be deemed to have approved such legal counsel;

 

		6.4.2.2.	Yeda
                                         may elect, at its own initiative, to join as a party to such suit; and

 

		6.4.2.3.	Yeda
                                         may elect to be represented in such suit by the Company’s choice of legal counsel, or
                                         at any time during such suit, engage its own legal counsel therein.

 

		6.5.	With
regard to any action or proceeding to which the Company is a party referred to in clauses 6.3 and 6.4 above (“Company
Litigation”):

 

		6.5.1.	Subject
                                         to the Company’s compliance with its obligation to bear Litigation Expenses as aforesaid,
                                         Yeda shall cooperate and shall use its reasonable efforts to cause the Scientists to
                                         cooperate with the Company in prosecuting or defending such Company Litigation, as relevant.

 

		6.5.2.	No
                                         settlement, consent order, consent judgment or other voluntary final disposition of any
                                         Company Litigation may be entered into without the prior written consent of Yeda, which
                                         consent shall not be unreasonably withheld in the case of settlements for monetary damages
                                         payable by the Company or by the counterparty in such Company Litigation only. Moreover,
                                         Yeda shall not unreasonably delay its response to any request for such consent.

 

		6.5.3.	Any
                                         recovery in any Company Litigation shall first be applied to cover costs and thereafter
                                         shall be deemed to be Sublicensing Receipts, entitling Yeda to consideration in respect
                                         thereof as set out in clause 9 below and divided between the Company and Yeda accordingly.

 

    - 26 -

     

    

 

		6.5.4.	The
                                         Company shall promptly keep Yeda informed and provide copies to Yeda of all documents
                                         regarding all Company Litigation instituted by or against the Company.

 

		6.6.	The
provisions of clauses 6.4 and 6.5 notwithstanding, if any proceeding of any nature which could lead to the invalidity of
the Yeda Patents is brought before any authority (a “Patent Challenge”), then Yeda shall have the right (but
not the obligation) to take over the sole defence of such Patent Challenge.

 

		6.7.	If
Yeda shall take over the sole defence of a Patent Challenge as aforesaid, or shall commence suit for infringement and misappropriation
in accordance with clause 6.3.6 above, then Yeda shall take the relevant action or proceedings at Yeda’s expense, and the
Company shall co-operate in such Patent Challenge or suit (either such matter an “Action”) at the Company’s
expense and, if required under applicable law or contract, consent to be named as a party to any such Action. Yeda shall have
full control of such Action and shall have full authority to settle such Action on such terms as Yeda shall determine. Any recovery
in any such Action shall first be applied to cover the parties’ respective costs (pro rata if the recovery amount is insufficient
to cover such costs in full), and shall thereafter be applied as follows: if deriving from a suit for infringement and misappropriation
commenced by Yeda in accordance with clause 6.3.6 above, to be for the account of Yeda only; but if deriving from the assumption
by Yeda of the sole defence of a Patent Challenge brought within the framework of a suit for infringement or misappropriation
brought by the Company as aforesaid, to be split between the parties pro rata to the out-of-pocket costs that each of them incurred
in connection with such proceedings.

 

    - 27 -

     

    

 

		7.	Licence

 

		7.1.	Yeda
                                         hereby grants the Licence to the Company, and the Company hereby accepts the Licence
                                         from Yeda, during the period, for the consideration and subject to the terms and conditions
                                         set out in this Agreement. For the avoidance of doubt: (i) no licence is granted hereunder
                                         with regard to any patents or patent applications or other intellectual property (owned
                                         now or in the future by Yeda or the Institute), other than the Patents and intellectual
                                         property in the Know-How; and (ii) no licence is granted with respect to the use of bacteriophages
                                         to treat against free-living bacteria (such as for environmental treatment) outside the
                                         human organism, provided that there shall be no restriction on the Company developing
                                         such treatments independently of the Institute or Yeda without any use of the Licensed
                                         Information or the Subsequent Results;

 

		7.2.	The
                                         Licence shall remain in force in each country in the world (with respect to each Product
                                         (if not previously terminated in accordance with the provisions of this Agreement) until
                                         the later of:

 

		7.2.1.	the
                                         date of expiry in such country of the last of any Patent (including, for the avoidance
                                         of doubt, any patent application, as referred to in the definition of “Patents”
                                         in clause 1.2.20 above) in such country covering such Product to expire; or

 

		7.2.2.	if
                                         there is any Licensed Information, Initial Research Results or Subsequent Results that
                                         is or are identifiable, secret and of value relating to such Product, the date of expiry
                                         of a period of 11 (eleven) years commencing on the date of First Commercial Sale by the
                                         Company or a Sublicensee of such Product in such country.

 

For
the purposes of clause 7.2.1 above and clause 9.1.2 below, a Product shall be deemed to be covered by a Patent in any
country even after the Patent in such country covering such Product has expired, in the event that, and for so long as, such Product
is protected and/or covered by “Orphan Drug” status as referred to in clause 6.1.2 above, paediatric use approval
and/or by any type of data exclusivity (including any exclusivity granted in respect of biological products pursuant to the US
Biologics Price Competition and Innovation Act) or data protection or by any other regulations and/or provisions granting similar
statutory or regulatory protection of such Product in such country (each of the aforegoing, “Additional Protection”).

 

The
Company shall notify Yeda in writing immediately upon the making of each such First Commercial Sale referred to in clause 7.2.2
above, specifying its date, the country in which such sale took place and the type of Product sold.

 

    - 28 -

     

    

 

At
the end of the term of the Licence in a country or countries with respect to any Product as set forth above, subject to the Company’s
continued compliance with the terms of this Agreement, the Company shall have a fully paid-up, royalty-free, exclusive, freely
sublicenseable and assignable, perpetual and irrevocable licence in relation to the intellectual property included in the Licence
and constituting know-how in such country or countries with respect to such Product which has not at such time become part of
the public domain.

 

With
respect to each Other Product, the Licence shall remain in force in each country in the world for so long as this Agreement has
not been terminated in accordance with the provisions of this Agreement.

 

		7.3.	A
                                         Sublicence under the Licence with respect to Products may be granted by the Company without
                                         the prior written consent of Yeda, provided that:

 

		7.3.1.	the
                                         proposed Sublicence is for monetary consideration or money’s worth only;

 

		7.3.2.	the
                                         proposed Sublicence is to be granted in a bona fide arms-length commercial transaction,
                                         or if the proposed Sublicence is to be granted to an Affiliated Entity or a shareholder
                                         of the Company, such Sublicence shall be granted on market terms;

 

		7.3.3.	a
                                         draft of the proposed Sublicence (either final or close to final) is submitted to Yeda
                                         at least [***] prior to the signature thereof;

 

		7.3.4.	the
                                         proposed Sublicence is made by written agreement, the provisions of which are consistent
                                         with the terms of the Licence and contain, inter alia, the following terms and
                                         conditions:

 

		7.3.4.1.	the
                                         Sublicence shall expire automatically on the termination of the Licence for any reason,
                                         provided, however, that if pursuant to such Sublicence, such Sublicensee
                                         is granted an exclusive worldwide Sublicence in respect of one or more Products, and
                                         if such Sublicensee is not at the time of such termination in breach of its Sublicence
                                         with the Company such that the Company would have the right to terminate such Sublicence,
                                         Yeda shall be obligated, if such Sublicensee shall so request within [***] from the date
                                         of such termination, to negotiate in good faith with such Sublicensee the grant to such
                                         Sublicensee of a licence upon the same terms and conditions as this Agreement, or if
                                         applicable, in view of the scope of the Sublicence, substantially the same terms and
                                         conditions as this Agreement, for the development, testing manufacture, production, and
                                         sale of such Product or Products, mutatis mutandis, as if such Sublicensee had
                                         been the original licensee hereunder in respect of such Product or Products, provided
                                         that such Sublicensee has also agreed to indemnify Yeda, to Yeda’s satisfaction,
                                         against any losses or damage (including legal costs) resulting from or in connection
                                         with any claims brought by the Company following or in connection with such termination;

 

    - 29 -

     

    

 

		7.3.4.2.	the
                                         Company shall have audit rights vis-à-vis the Sublicensee consistent with Yeda’s
                                         rights under clause 9.5, and should the Company fail to exercise its rights thereunder,
                                         following Yeda’s demand, Yeda shall be entitled to appoint its representative to carry
                                         out such inspection in the Company’s stead.

 

		7.3.4.3.	the
                                         Sublicensee shall be bound by provisions substantially similar to those in clause 10
                                         below relating to confidentiality binding the Company (the obligations of the Sublicensee
                                         so arising being addressed also to Yeda directly);

 

		7.3.4.4.	an
                                         exclusion of liability and indemnification undertaking in the same form, mutatis mutandis,
                                         as the provisions of clause 12 below (the indemnification obligations of the Sublicensee
                                         to be given also in favour of, and shall be actionable by Yeda, the Institute, any director,
                                         officer or employee of Yeda or of the Institute, or by the Inventors);

 

		7.3.4.5.	all
                                         terms necessary to enable performance by the Company of its obligations hereunder;

 

		7.3.4.6.	that
                                         the Sublicence shall not be assignable, otherwise transferable or further sublicenseable,
                                         save that the Sublicence shall be further sublicenseable (“Further Sublicence”)
                                         provided that:

 

		(i)	the
proposed Further Sublicence shall be consistent, mutatis mutandis, with the provisions of clauses 7.3.1, 7.3.2, 7.3.4.1
(other than the proviso thereto) to 7.3.4.5, this clause 7.3.4.6 and 7.3.4.7 as if references in such clauses to “Sublicence”
or “Sublicensee” were references to “Further Sublicence” or “Further Sublicensee” respectively;

 

    - 30 -

     

    

 

		(ii)	the
                                         proposed Further Sublicence shall not be assignable, otherwise transferable or further
                                         sublicenseable; and

 

		(ii)	any
                                         act or omission by the Further Sublicensee which would have constituted a breach of this
                                         Agreement by the Company had it been the act or omission of the Company shall constitute
                                         a breach of the Further Sublicence entitling the Sublicensee to terminate the Sublicence,
                                         and the Company hereby undertakes to procure that the Sublicensee will be obliged to
                                         inform the Company of such breach, to inform Yeda forthwith upon receipt of knowledge
                                         by the Company of such breach and, at the request of Yeda, and at the Company’s
                                         cost and expense, to procure that the Sublicensee shall exercise such right of termination.

 

In
the event that a Further Sublicence shall be granted, all references in this Agreement to a Sublicensee shall be deemed to include
references to a Further Sublicensee (for the avoidance of doubt, including in the definition of Net Sales and with respect to
all payment obligations pursuant to clause 9 below).

 

		7.3.4.7.	that:
                                         (i) a copy of the agreement granting the Sublicence shall be made available to Yeda,
                                         within [***] of its execution; (ii) no amendments shall be made to any such Sublicence
                                         agreement which are not consistent with the criteria set out in this clause 7.3.4; and
                                         (iii) the Company shall submit to Yeda copies of all such amendments (as approved
                                         by Yeda, if required), promptly upon execution thereof;

 

and

 

		7.3.5.	any
                                         act or omission by the Sublicensee which would have constituted a breach of this Agreement
                                         by the Company had it been the act or omission of the Company, and which is not cured
                                         during the relevant cure period pursuant to this Agreement shall constitute a breach
                                         of the Sublicence with the Company entitling the Company to terminate the Sublicence,
                                         and the Company hereby undertakes to inform Yeda forthwith upon receipt of knowledge
                                         by the Company of such uncured breach and, at the request of Yeda, and at the Company’s
                                         cost and expense, to exercise such right of termination.

 

    - 31 -

     

    

 

		7.4.	A
                                         Sublicence under the Licence with respect to Other Products may be granted by the Company
                                         without the prior written consent of Yeda, provided only that the provisions of clauses
                                         7.3.4.1 (other than the proviso thereto), 7.3.4.3, 7.3.4.4 and 7.3.5 above shall apply
                                         thereto.

 

		7.5.	For
                                         the avoidance of doubt, the Company shall not be entitled to grant, directly or indirectly,
                                         to any person or entity any right of whatsoever nature to exploit or use in any way the
                                         Licensed Information, the Subsequent Results, the Yeda Patents or the Joint Patents with
                                         respect to Products or Other Products or to develop, test, manufacture, produce and/or
                                         sell the Products or Other Products or any part of any of the aforegoing, save by way
                                         of Sublicence within the meaning of such term in clause 1.2.26 above or by way of
                                         a Subcontract with a Subcontractor and a distribution agreement with a Distributor and
                                         subject to the conditions of this clause 7 relating to any such grant.

 

		7.6.	The
                                         Company and/or its Sublicensees shall be entitled to enter into Subcontracts with Subcontractors
                                         and distribution agreements with Distributors without obtaining Yeda’s consent,
                                         provided that: (i) with regard to any agreement with such Distributor the terms
                                         of clauses 7.3.4.1, 7.3.4.2 and 7.3.4.4 and 7.3.4.5 are observed, mutatis mutandis;
                                         (ii) without in any way derogating from the Company’s obligations under this Agreement,
                                          the Company shall be liable to Yeda for any loss or damage caused to Yeda in connection
                                         with or resulting from the grant of such rights; and (iii) any sales of Products
                                         made by any Distributor shall only be without making any alteration to such Products.
                                         The Company shall provide Yeda with a copy of all agreements entered into with Distributors
                                         as part of any audit carried out by Yeda pursuant to clause 9.5 below.

 

    - 32 -

     

    

 

		7.7.	The
                                         parties acknowledge that the Scientists plan to attempt to develop outside of the Research
                                         Program at the Institute a unique animal model intended to combine genetic and Microbiota
                                         simulation of inflammatory bowel disease (“Currently Planned Model”).
                                         In addition, the Scientists may develop, outside of the Research Program, other unique
                                         animal models intended to combine genetic and Microbiota simulation of human diseases,
                                         which Yeda and the Company may (without being under any obligation to do so) expressly
                                         agree are to be used within the framework of an agreed Research Program (such other unique
                                         animal models as aforesaid, which Yeda and the Company have in fact expressly agreed
                                         are to be used within the framework of an agreed Research Program, “Other Models”).
                                         In the event that the Currently Planned Model or any Other Models (collectively “Models”)
                                         are developed as aforesaid, then, during the term hereof, for such time as such Models
                                         are reasonably available, Yeda will use good faith efforts to procure that the Company
                                         will be provided with (and shall be granted a non-exclusive licence to use) such Models
                                         (if and when developed and, with respect to Other Models, for the avoidance of doubt,
                                         if Yeda and the Company have in fact expressly agreed that such Other Models are to be
                                         used within the framework of an agreed Research Program), at the actual cost of provision
                                         of such service, solely for the purpose of use as tools in enhancing the development
                                         of Products within the framework of the development of Products as referred to in clause
                                         8 below, with no additional consideration being due to Yeda or to the Scientists in respect
                                         of such use, subject to the compliance by the Company with all conditions (determined
                                         by Yeda, the Institute, the Scientists or otherwise) necessary to permit such use (including,
                                         if so required by Yeda, the signature of a separate material transfer or services agreement)
                                         and subject to Yeda’s obligations to any third party that may fund or own the Models
                                         or components thereof (though the Company will not be afforded entry to the facility
                                         where the Models are kept). For purposes hereof, actual cost of the provision of such
                                         services means the actual out-of-pocket cost, plus overhead, in accordance with the Institute’s
                                         customary terms, of providing the Models, and not any development costs. For the avoidance
                                         of doubt, all right, title and interest in the Models shall remain with Yeda, and any
                                         data and results that may be generated from the Company’s use of the Models shall be
                                         deemed Subsequent Results and jointly owned pursuant to clause 5.1.2. The parties acknowledge
                                         that the Research Program (Appendix C) envisages the use of the Currently Planned Model,
                                         if developed and available in the course of the Research.

 

    - 33 -

     

    

 

		7.8.	For
                                         the avoidance of doubt, nothing contained in this Agreement shall prevent Yeda or the
                                         Institute or the Inventors from using the Licensed Information, the Subsequent Results,
                                         the Yeda Patents and the Joint Patents for internal academic research, which shall include
                                         transfer to other scientists of the Institute. Yeda and the Institute shall not transfer
                                         phages or sequences of phages created within the framework of the Research financed by
                                         the Company in accordance with the provisions of this Agreement, to any third party,
                                         including scientists at institutions other than the Institute. Other materials and data
                                         created within the framework of the Research financed by the Company in accordance with
                                         the provisions of this Agreement may be transferred by Yeda and the Institute to scientists
                                         at institutions other than the Institute solely for academic research purposes and only
                                         under a Material Transfer Agreement in the form attached hereto as Appendix E.

 

		8.	Development
                                         and CommercialiSation

 

		8.1.	The
                                         Initial Development Program is attached hereto as Appendix F. The Company will
                                         submit to Yeda copies of all additional or amended Development Programs for the development
                                         of Products as approved by the Company’s board of directors from time to time following
                                         the date hereof, as soon as practicable after the date of approval (each such Development
                                         Program a “Development Program”). The foregoing notwithstanding, the
                                         Company undertakes to submit copies of the following Development Programs: (i) during
                                         the Incubator Period, such development programs as are filed with the OCS, and (ii) within
                                         [***] of the end of the Incubator Period, a Development Program covering the period up
                                         to the end of Phase I clinical studies for at least [***] Products, to include milestones
                                         at intervals of no more than [***].

 

		8.2.	The
                                         Company is of the opinion that the Existing Know-How is revolutionary and that to the
                                         best of its knowledge, no product containing phages has been approved as a therapeutic
                                         to date. As the scientific, technical and regulatory hurdles that will be encountered
                                         in developing, producing, testing and registering Licensed Products cannot be assessed
                                         at present, the Company cannot commit to carrying out the Development Programs within
                                         set time frames. The Company does undertake, however, at its own expense, to use commercially
                                         reasonable efforts to expedite the commencement of the commercial sale of the Products
                                         (compliance with such obligation will be evaluated on the basis of current industry standards
                                         for research and development activities applicable to companies of similar size as the
                                         Company as generally applied to products of similar potential at similar stages in their
                                         life cycles), and to make commercially reasonable efforts to raise sufficient funds to
                                         carry out the Development Programs. The Company further undertakes to continue with development
                                         and/or commercialisation of at least [***] Products diligently throughout the period
                                         of the Licence.

 

    - 34 -

     

    

 

		8.3.	During
                                         the Incubator Period, the Company shall provide Yeda with copies of the reports that
                                         it submits to the OCS. Thereafter, on [***] of each calendar year, the Company shall
                                         provide Yeda with written progress reports (“Progress Reports”) which
                                         shall include descriptions of the progress and results, if any, of: (i) the tests
                                         and trials (if applicable) conducted and all other actions taken by the Company pursuant
                                         to the Initial Development Program or any other Development Program; (ii) manufacturing,
                                         sublicensing, marketing and sales; (iii) the Company’s plans in respect of
                                         the testing, undertaking of trials (if applicable) or commercialisation of Products;
                                         and (v) the amount of money invested in the Company during the preceding [***].
                                         If the Company has provided a Development Program for more than 1 (one) Product, then
                                         such Progress Report shall provide such information separately for each such Product.
                                         The Company shall also provide any reasonable additional data that Yeda requires to evaluate
                                         the performance of the Company hereunder.

 

		8.4.	For
                                         the avoidance of doubt, without derogating from the remaining provisions of this clause 8
                                         or of clause 13.2 below, nothing contained in this Agreement shall be construed
                                         as a warranty by the Company that any Development Program to be carried out by it as
                                         aforesaid will actually achieve its aims and the Company makes no warranties whatsoever
                                         as to any results to be achieved in consequence of the carrying out of any such Development
                                         Program.

 

		8.5.	The
                                         Company shall mark, and cause all its Sublicensees and Distributors to mark, all Products
                                         (including any Companion Diagnostic Kits of any Products) that are manufactured or sold
                                         under this Agreement with the number or numbers of each Patent applicable to such Product
                                         (or Companion Diagnostic Kit, as applicable).

 

    - 35 -

     

    

 

		8.6.	Without
                                         derogating from the aforegoing in this clause 8, the Company undertakes that an
                                         average of [***], calculated on a [***] rolling basis (meaning, in respect of [***]),
                                         (but no less than [***]) will be invested (by the Company and/or by a Sublicensee, if
                                         a Sublicence has been entered into) in the development of Products, [***].

 

		9.	Royalties

 

		9.1.	In
                                         consideration for the grant of the Licence, the Company shall pay Yeda:

 

		9.1.1.	a
                                         non-refundable licence fee of US $10,000 (ten thousand) United States Dollars) per
                                         year (or part thereof) during the term of this Agreement (“the Annual Licence
                                         Fee”) to be paid in advance at [***] during the term of this Agreement, commencing
                                         on [***] following the date on which the written report at the end of the Research Period,
                                         as referred to in clause 4.1 above, was provided to the Company, and thereafter on each
                                         1 January during the term of the Licence;

 

		9.1.2.	the
                                         following royalty amounts:

 

		9.1.2.1.	a
                                         royalty of the following percentages of Net Sales of WIS Products (including any Companion
                                         Diagnostic Kits of any such WIS Products) by or on behalf of the Company or any Sublicensees:

 

		a)	[***]
on Net Sales [***];

 

		b)	[***]
                                         on Net Sales [***]; and

 

		c)	[***]
                                         on Net Sales [***];

 

and

 

    - 36 -

     

    

 

		9.1.2.2.	a
                                         royalty of the following percentages of Net Sales by or on behalf of the Company of Company
                                         Products (including any Companion Diagnostic Kits of any such Company Products):

 

		a)	[***]
                                         on Net Sales [***];

 

		b)	[***]
                                         on Net Sales [***]; and

 

		c)	[***]
                                         on Net Sales [***];

 

provided
that in respect of Group 2 Company Products which were Discovered during the [***] period commencing [***], such rates will be
payable [***], and in respect of Group 2 Company Products which were Discovered during subsequent [***] periods commencing [***],
such rates will be payable [***] per each [***] period starting as from [***].

 

provided
further that:

 

		i)	in
                                         the event that there are any sales of a Product in any country that are not, at the time
                                         of such sales, covered by a Patent (within the meaning of such term in clause 1.2.20
                                         above) and/or by Additional Protection as referred to in the third last paragraph of
                                         clause 7.2 above, in such country, then the royalty rate referred to in clauses 9.1.2.1
                                         and 9.1.2.2 above shall, with respect to Net Sales of such Product made in such country
                                         during the period such Product is not so covered by a Patent as aforesaid, be reduced
                                         by [***], or by [***] upon the commencement of sale in such country of a product which
                                         is a Generic Equivalent to such Product. In this clause 9.1.2, “a Generic
                                         Equivalent” shall, with respect to any Product, mean a product in respect of
                                         which the following applies: (1) such product has the same active ingredient as such
                                         Product; and (2) such product has a full and unchallenged marketing approval as a generic
                                         equivalent of such Product by the appropriate regulatory authority and, in each case,
                                         is administered by a mode of administration substantially similar to such Product; and

 

    - 37 -

     

    

 

		ii)	if,
                                         after arm’s length bona fide negotiations, the Company enters into a licence agreement
                                         with any third party the subject matter of which licence is employed in the provision
                                         of technologies for production, manufacturing, stabilisation, storage, quality assurance
                                         or delivery of a Product or other active ingredients thereof, or which licence is required
                                         in order to prevent the infringement by a Product of the rights of such third party,
                                         the Company may reduce the royalty rate applicable hereunder (only with respect to any
                                         Product and in any country to which such licence relates) by [***] of the additional
                                         royalty rate beyond the first [***] payable to such third party; provided, however, that
                                         in no event will the royalty rate otherwise due to Yeda be reduced to less than [***]
                                         of the percentages set out in 9.1.2.1(a) to (c) and 9.1.2.2(a) to (c) above;

 

	 	 	and
	 	 	 
		9.1.3.	the
                                         following percentages of all Sublicensing Receipts:

 

		a)	[***]
                                         of all Sublicensing Receipts [***];

 

		b)	[***]
                                         of all Sublicensing Receipts [***];

 

		c)	[***]
                                         of all Sublicensing Receipts [***];

 

		d)	[***]
                                         of all Sublicensing Receipts [***];

 

provided,
however, that:

 

		i)	the
                                         amount payable to Yeda as a percentage of Sublicensing Receipts in respect of amounts
                                         received by the Company which constitute royalties based on sales of Company Products
                                         by Sublicensees shall not be less than an amount equal to [***] of the Net Sales of [***];
                                         and

 

		ii)	in
                                         the event that payment from a Sublicensee to the Company in respect of Net Sales of Company
                                         Products shall, pursuant to the relevant Sublicence, cease due to lack of exclusivity
                                         or Patent protection as aforesaid, the Company will be relieved of its obligations to
                                         pay royalties on Net Sales of Company Products by Sublicensees pursuant to clause 9.1.2.1;

 

		iii)	for
                                         the avoidance of doubt, Yeda shall be entitled to receive percentages of Sublicensing
                                         Receipts which constitute royalties based on sales of Group 2 Company Products by Sublicensees
                                         in respect of the entire term of such Sublicence, including after the term of this Agreement;
                                         the provisions of this clause shall survive the termination or expiry of this Agreement;
                                         and

 

    - 38 -

     

    

 

		iv)	Yeda
                                         shall not be entitled to receive percentages of Sublicensing Receipts under Sublicenses
                                         that pertain solely to Other Products.

 

For
the avoidance of doubt, the Company undertakes that all sales (within the meaning of such term in clause 1.3.4 above) of
Products by the Company and each Sublicensee shall be for cash consideration only, save for reasonable quantities of Products
provided for testing, registration and marketing purposes.

 

		9.2.	In
                                         calculating Net Sales, Sublicensing Receipts, all amounts shall be expressed in US Dollars
                                         and any amount received or invoiced in a currency other than US Dollars shall be
                                         translated into US Dollars, for the purposes of calculation, in accordance with the Exchange
                                         Rate between the US Dollar and such currency on the date of such receipt or invoice,
                                         as the case may be. For the avoidance of doubt, in calculating amounts received by the
                                         Company, whether by way of Net Sales or Sublicensing Receipts, any amount deducted or
                                         withheld in connection with any payment to the Company, on account of taxes on net income
                                         (including income taxes, capital gains tax, taxes on profits or taxes of a similar nature)
                                         payable by the Company in any jurisdiction, shall be deemed, notwithstanding such deduction
                                         or withholding, as having been received by the Company; provided that, in the case of
                                         a deduction or withholding in respect of Sublicensing Receipts only, in the event that
                                         the Company would not under Israeli or other applicable law be entitled to claim a corresponding
                                         tax credit or reimbursement in respect of the amount deducted or withheld, even assuming
                                         that in the relevant tax year the Company were to be liable to pay tax in Israel or other
                                         applicable jurisdiction, such amount would not be deemed to be a Sublicensing Receipt.

 

		9.3.	

 

		9.3.1.	Amounts
                                         payable to Yeda in terms of this clause 9 shall be paid to Yeda in US Dollars:
                                         (i) in the case of Net Sales, on a [***] and no later than [***] after the end of
                                         each [***] (provided that with respect only to the first [***] in which any Net Sales
                                         are made, the payment for such [***] will be made within [***] after the end of the [***]);
                                         or (ii) in the case of Sublicensing Receipts, no later than [***] after any such
                                         Sublicensing Receipts are received by the Company from any Sublicensees.

 

    - 39 -

     

    

 

		9.3.2.	The
                                         Company shall submit to Yeda: (i) no later than [***] after any Sublicensing Receipts
                                         are received, an interim written report setting out amounts owing to Yeda in respect
                                         of such Sublicensing Receipts, and (ii) no later than [***] after the end of each
                                         [***], commencing with the [***] in which any Net Sales are made or Sublicensing Receipts
                                         are received by the Company, a report, in a form acceptable to Yeda, certified as being
                                         correct by the chief financial officer of the Company, setting out all amounts owing
                                         to Yeda in respect of such previous [***] (or with respect to the [***] in which any
                                         Net Sales are made, the [***]) to which the report refers, and with full details of:

 

		9.3.2.1.	(i)	the sales made by the Company and Sublicensees, including
a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products
(including any Companion Diagnostic Kits of any Products)sold;

 

		(ii)	the
                                         Sublicensing Receipts, including a breakdown of Sublicensing Receipts according to identity
                                         of Sublicensees, countries, the currency of the payment and date of receipt thereof;

 

		(iii)	deductions
                                         applicable, as provided in the definition of “Net Sales”; and

 

		(iv)	any
                                         other matter necessary to enable the determination of the amounts of royalties payable
                                         hereunder.

 

		9.4.	The
                                         Company shall keep and shall contractually oblige its Sublicensees to keep complete,
                                         accurate and correct books of account and records consistent with sound business and
                                         accounting principles and practices and in such form and in such details as to enable
                                         the determination of the amounts due to Yeda in terms hereof. The Company shall supply
                                         Yeda at the end of each [***], commencing with the [***] in which any amount is payable
                                         by the Company to Yeda under this clause 9, a report signed by the Company’s
                                         chief financial officer in respect of the amounts due to Yeda pursuant to this clause 9
                                         in respect of the year covered by the said report and containing details in accordance
                                         with clause 9.3 above in respect of the [***] reports. The Company shall retain
                                         and shall require and contractually oblige its Sublicensees to supply it with similar
                                         reports which may be divulged to Yeda’s representatives pursuant clause 9.5 and to retain
                                         the aforegoing books of account for [***] after the end of each [***] during the period
                                         of this Agreement, and, if this Agreement is terminated for any reason whatsoever, for
                                         [***] after the end of the [***] in which such termination becomes effective.

 

    - 40 -

     

    

 

		9.5.	At
                                         Yeda’s expense, Yeda shall be entitled to appoint representatives to inspect during normal
                                         business hours and to make copies of the Company’s books of account, records and
                                         other documentation (including technical data and lab books) to the extent relevant or
                                         necessary for the ascertainment or verification of the amounts due to Yeda under this
                                         clause 9, provided however that Yeda shall coordinate such inspection with the Company
                                         in advance. The Company shall take all steps necessary so that all such books of account,
                                         records and other documentation of the Company is available for inspection as aforesaid
                                         at a single location. Yeda shall not be entitled to exercise this right more than [***]
                                         a year. In the event that any inspection as aforesaid reveals any underpayment by the
                                         Company to Yeda in respect of any year of the Agreement in an amount exceeding [***]
                                         of the amount actually paid by the Company to Yeda in respect of such year then the Company
                                         shall (in addition to paying Yeda the shortfall together with interest thereon in accordance
                                         with clause 18.7 below), bear the costs of such inspection. The Company shall inspect
                                         and obtain copies of any Sublicensee’s books of account, records and other documentation
                                         (including technical data and lab books) to the extent relevant or necessary for the
                                         ascertainment or verification of the amounts due to Yeda under this clause 9 in
                                         accordance with the provisions of this clause 9.5, mutatis mutandis, provided
                                         that if the Company shall fail, following Yeda’s demand, to carry out such inspection,
                                         Yeda shall be entitled to exercise such rights of inspection with regard to any Sublicensee.
                                         The provisions of this clause 9.5 shall survive the termination of this Agreement
                                         for whatsoever reason for a period of [***] after the end of the calendar year in which
                                         such termination becomes effective.

 

    - 41 -

     

    

 

		10.	Confidentiality

 

		10.1.	The
                                         Company shall maintain in confidence all information or data relating to the Patents,
                                         the Licensed Information, the Subsequent Results, this Agreement and the terms hereof
                                         (hereinafter, collectively referred to as “the Confidential Information”),
                                         except and to the extent that the Company can prove that any such information or data
                                         is in the public domain at the date of the signing hereof or becomes part of the public
                                         domain thereafter (other than through a violation by the Company or a Sublicensee or
                                         a Distributor of this obligation of confidentiality) and except with regard to that portion,
                                         if any, of the Confidential Information expressly released by Yeda from this obligation
                                         of confidentiality by notice in writing to the Company to such effect. Notwithstanding
                                         the foregoing, the Company may disclose to its personnel, Distributors and Sublicensees,
                                         potential investors, FutuRx and the Incubators Committee the Confidential Information
                                         to the extent necessary for the exercise by it of its rights hereunder or in the fulfilment
                                         of its obligations hereunder, provided that it shall bind any such persons or entities
                                         with a similar undertaking of confidentiality in writing. The Company shall be responsible
                                         and liable to Yeda for any breach by its personnel or any Distributor or any Sublicensee
                                         of such undertakings of confidentiality as if such breach were a breach by the Company
                                         itself.

 

		10.2.	In
                                         addition to and without derogating from the aforegoing, the Company undertakes not to
                                         make mention of the names of Yeda, the Inventors, the Institute or any scientists or
                                         other employees of the Institute or any employee of Yeda in any manner or for any purpose
                                         whatsoever in relation to this Agreement, its subject-matter and any matter arising from
                                         this Agreement or otherwise, unless the prior written approval of Yeda thereto has been
                                         obtained.

 

		10.3.	Notwithstanding
                                         the provisions of clauses 10.1 and 10.2 above, the Company shall not be prevented
                                         from mentioning the name of Yeda, the Inventors, the Institute and/or any scientists
                                         or other employees of the Institute or any employee of Yeda or from disclosing any information
                                         if, and to the extent that, such mention or disclosure is to competent authorities for
                                         the purposes of obtaining approval or permission for the exercise of the Licence, or
                                         in the fulfilment of any legal duty owed to any competent authority (including a duty
                                         to make regulatory filings); The text that the Company may use in context of fundraising
                                         such as in a private placement memorandum or a public offering registration statement
                                         is attached hereto as Appendix G. Any other mention shall be subject to Yeda’s
                                         consent, which consent shall not be withheld unreasonably.

 

    - 42 -

     

    

 

		10.4.	Yeda
                                         shall maintain in confidence all information received by Yeda from the Company which
                                         has been designated by the Company in writing and in advance as confidential as well
                                         as all plans and reports received from the Company hereunder (including reports originating
                                         with its Affiliated Entities and Sublicensees), except and to the extent that: (i) any
                                         such information or data is in the public domain at the date of the signing hereof or
                                         becomes part of the public domain thereafter (other than through a violation by Yeda
                                         of this obligation of confidentiality) or is released by the Company from this obligation
                                         of confidentiality by notice in writing; (ii) Yeda is required to disclose such
                                         information in order to fulfil its obligations under this Agreement (including in connection
                                         with the filing and prosecution of patent applications in accordance with the provisions
                                         of clause 6 above); or (iii) Yeda is required to disclose such information
                                         in fulfilment of any legal duty owed to any competent authority (the Company hereby acknowledging
                                         that it is aware that such competent authority may not be bound by any confidentiality
                                         obligations and may disclose or be required to disclose such information to a third party,
                                         whether by order of court or by law or otherwise). For the avoidance of doubt, the provisions
                                         of this clause 10.4 shall not apply in respect of any information (not being Licensed
                                         Information) independently developed at the Institute without reference to the confidential
                                         information received from the Company.

 

		10.5.	For
                                         the avoidance of doubt, Yeda shall have the right to allow the scientists of the Institute
                                         to publish articles relating to the Licensed Information and the Subsequent Results in
                                         scientific journals or posters or to give lectures or seminars to third parties relating
                                         to the Licensed Information, on the condition that, to the extent that the information
                                         to be published or disclosed is Licensed Information which is not in the public domain,
                                         a draft copy of the said contemplated publication or disclosure shall have been furnished
                                         to the Company at least [***] before the making of any such publication or disclosure
                                         and the Company shall have failed to notify Yeda in writing, within [***] from receipt
                                         of the said draft publication or disclosure, of its opposition to the making of the contemplated
                                         publication or disclosure. Should the Company notify Yeda in writing within [***] from
                                         the receipt of the draft contemplated publication or disclosure that it opposes the making
                                         of such publication or disclosure because it includes material (which has been specified
                                         in said notice) in respect of which there are reasonable grounds (which have also been
                                         specified in said notice) requiring the postponement of such publication or disclosure
                                         so as not adversely to affect the Company’s interests under the Licence because such
                                         Licensed Information is patentable subject-matter for which patent protection pursuant
                                         to clause 6.1 above should be sought, then Yeda shall not permit such publication
                                         or disclosure unless and until there shall first have been filed an appropriate patent
                                         application in respect of the material to be published or disclosed as aforesaid. The
                                         Company acknowledges that it is aware of the importance to the researchers of publishing
                                         their work and, accordingly, the Company will use its best efforts not to oppose such
                                         publications. In no event may any such publications contain the Confidential Information
                                         of the Company.

 

    - 43 -

     

    

 

		10.6.	The
                                         obligations of the parties under this clause 10 shall survive any termination of
                                         this Agreement for a period of [***] (other than Yeda’s obligations pursuant to clause
                                         10.5 which shall terminate upon the termination of this Agreement), but without derogating
                                         from Yeda’s right to commercialise pursuant to clause 13.5 below.

 

		11.	Assignment

 

The
Company may assign or encumber all of its rights or obligations under this Agreement or arising therefrom, provided that (save
where any such assignment would constitute an event entitling Yeda to an Exit Fee as set out in clause 15 below) any consideration
received by the Company in respect of an assignment as aforesaid shall be deemed to be Sublicensing Receipts, entitling Yeda to
consideration as set out in clause 9.1.3(b) to (d) above, and to which the other relevant provisions of clause 9 above shall
apply, mutatis mutandis. Any assignment permitted under this clause 11 shall be subject to the assignee undertaking to
Yeda in writing, in a form reasonably acceptable to Yeda, to be bound by all obligations of the Company under this Agreement.

 

    - 44 -

     

    

 

		12.	Exclusion
                                         of Liability and Indemnification

 

		12.1.	Yeda,
                                         the Inventors, the Institute and the directors, officers and employees of Yeda and/or
                                         of the Institute (hereinafter collectively “the Indemnitees”) shall
                                         not be liable for any claims, demands, liabilities, costs, losses, damages or expenses
                                         (including legal costs and attorneys’ fees) of whatever kind or nature (all of
                                         the aforegoing, collectively, “Liabilities”) caused to or suffered
                                         by any person or entity (including the Company or any Sublicensee or Further Sublicensee
                                         or Distributor of either) that directly or indirectly arise out of or result from or
                                         are encountered in connection with this Agreement or the exercise of the Licence, including
                                         directly or indirectly arising out of or resulting from or encountered in connection
                                         with: (i) the development, manufacture, sale or use of any of the Products or Other
                                         Products (including any Companion Diagnostic Kits of any Products or Other Products)
                                         by the Company, any Sublicensee, any Further Sublicensee, any Distributor or any person
                                         acting in the name of or on behalf of any of the aforegoing, or acquiring, directly or
                                         indirectly, any of the Products or Other Products (including any Companion Diagnostic
                                         Kits of any Products or Other Products) from any of the aforegoing; or (ii) the
                                         exploitation or use by the Company or any Sublicensee or any Further Sublicensee or any
                                         Distributor of the Licensed Information or any part thereof, including of any data or
                                         information given, if given, in accordance with this Agreement.

 

		12.2.	In
                                         the event that any of the Indemnitees should incur or suffer any Liabilities that directly
                                         or indirectly arise out of or result from or are encountered in connection with this
                                         Agreement or the exercise of the Licence as aforesaid in clause 12.1 above, or shall
                                         be requested or obliged to pay to any person or entity any amount whatsoever as compensation
                                         for any Liabilities as aforesaid in clause 12.1 above, then the Company shall indemnify
                                         and hold harmless such Indemnitees from and against any and all such Liabilities (including,
                                         for the avoidance of doubt, legal costs and attorneys’ fees). Without limiting
                                         the generality of the aforegoing, the Company’s indemnification as aforesaid and the
                                         exclusion of liability in clause 12.1 above shall extend to product liability claims
                                         and to damages, claims, demands, liabilities, losses, costs and expenses (in each case
                                         whether based in tort, contract or otherwise) attributable to death, personal injury
                                         or property damage or to penalties imposed on account of the violation of any law, regulation
                                         or governmental requirement.

 

    - 45 -

     

    

 

		12.3.	The
                                         Company shall at its own expense insure its liability pursuant to clause 12.2 above
                                         during the period beginning on the date of the signing of this Agreement and continuing
                                         during the entire period that the Licence is in force in any country, plus an additional
                                         period of [***]. Such insurance shall be in reasonable amounts and on reasonable terms
                                         in the circumstances, having regard, in particular, to the nature of the Products, and
                                         shall be subscribed for from a reputable insurance company. The named insured under such
                                         insurances shall be the Company, the Inventors, Yeda and the Institute and the beneficiaries
                                         thereof shall include also the respective employees, officers and directors of Yeda and
                                         the Institute. The policy or policies so issued shall include a “cross-liability”
                                         provision pursuant to which the insurance is deemed to be separate insurance for each
                                         named insured (without right of subrogation as against any of the insured under the policy,
                                         or any of their representatives, employees, officers, directors or anyone in their name)
                                         and shall further provide that the insurer will be obliged to notify each insured in
                                         writing at least [***] in advance of the expiry or cancellation of the policy or policies.
                                         The Company hereby undertakes to comply punctually with all obligations imposed upon
                                         it under such policy or policies and in particular, without limiting the generality of
                                         the aforegoing, to pay in full and punctually all premiums and other payments for which
                                         it is liable pursuant to such policy or policies. The Company shall be obliged to submit
                                         to Yeda copies of the aforesaid insurance policy or policies within [***] of the date
                                         of issue of each such policy.

 

		12.4.	The
                                         provisions of this clause 12 shall survive the termination of this Agreement for
                                         whatsoever reason but without derogating from Yeda’s right to commercialise pursuant
                                         to clause 13.5 below.

 

		13.	Term
                                         and Termination

 

		13.1.	Save
                                         as set out hereunder or unless otherwise agreed to in writing, this Agreement shall terminate
                                         upon the occurrence of the later of the following:

 

		13.1.1.	the
                                         date of expiry of the last of the Patents; or

 

		13.1.2.	the
                                         expiry of a continuous period of 15 (fifteen) years during which there shall
                                         not have been a First Commercial Sale of any Product in any country.

 

    - 46 -

     

    

 

		13.2.	The
                                         Company shall have the right to terminate this Agreement by [***] advance written notice
                                         to Yeda at any time prior to the First Commercial Sale in respect of the first Product,
                                         provided that such notice is accompanied by a written undertaking to Yeda that (i) the
                                         Company will not and does not intend to develop, test, manufacture, produce or sell WIS
                                         Products or Group 1 Company Products; and (ii) should the Company develop, test, manufacture,
                                         produce or sell Group 2 Company Products, the financial provisions of this Agreement
                                         relating thereto, including clauses 9.1.2.2 and 9.1.3, solely as relating to Group 2
                                         Company Products, shall continue to apply in accordance with their terms, as though this
                                         Agreement had remained in force and effect.

 

		13.3.	Notwithstanding
                                         anything to the contrary contained in this Agreement:

 

		13.3.1.	Yeda
                                         shall be entitled (without derogating from clause 7.3.4.1 above) to terminate the
                                         Licence hereunder, by written notice to the Company (effective immediately), such termination
                                         being its sole remedy in respect of the matters set out below, if:

 

		13.3.1.1.	the
                                         Company shall fail to meet the requirement set out in clause 8.6; or

 

		13.3.1.2.	the
                                         Company shall, at any given time, have fewer than [***] Products in active development
                                         or continuous sales (where “continuous sales” in relation to a Product shall
                                         mean that there shall not have been a period of [***] or more during which no sales of
                                         such Product shall have taken place (except as a result of force majeure or other factors
                                         beyond the control of the Company); or

 

		13.3.1.3.	a
                                         Phase I clinical study in respect of at least [***] Product shall not have commenced
                                         within [***] from the date projected by the Company pursuant to clause 8.1, unless the
                                         Company can demonstrate that it is making diligent efforts to achieve commencement of
                                         Phase I clinical studies as aforesaid.

 

    - 47 -

     

    

 

		13.3.2.	Without
                                         derogating from the aforegoing, Yeda shall be entitled to terminate this Agreement (unless
                                         previously terminated in accordance with the provisions of this Agreement), by written
                                         notice to the Company (effective immediately), if the Company challenges the validity
                                         of any of the Patents. If any such challenge is unsuccessful, the Company shall (in addition
                                         to Yeda’s right to terminate pursuant to this clause 13.3.2) pay to Yeda liquidated damages
                                         in the amounts of [***], such liquidated damages being a genuine pre-estimate of the
                                         damage that would be incurred by Yeda as a result of any such challenge.

 

		13.4.	Without
                                         derogating from the parties’ rights hereunder or by law to any other or additional remedy
                                         or relief, it is agreed that either Yeda or the Company may terminate this Agreement
                                         and the Licence hereunder by serving a written notice to that effect on the other upon
                                         or after: (i) the commitment of a material breach hereof by the other party, which
                                         material breach cannot be cured or, if curable, which has not been cured by the party
                                         in breach within [***] (or, in the case of failure by the Company to pay any amount due
                                         from the Company to Yeda pursuant to or in connection with this Agreement on or before
                                         the due date of payment, [***] after receipt of a written notice from the other party
                                         in respect of such breach, or (ii) the granting of a winding-up order in respect
                                         of the other party, or upon an order being granted against the other party for the appointment
                                         of a receiver, or if such other party passes a resolution for its voluntary winding-up,
                                         or if a temporary or permanent liquidator or receiver is appointed in respect of such
                                         other party, or if a temporary or permanent attachment order is granted on such other
                                         party’s assets, or a substantial portion thereof, or if such other party shall seek protection
                                         under any laws or regulations, the effect of which is to suspend or impair the rights
                                         of any or all of its creditors, or to impose a moratorium on such creditors, or if anything
                                         analogous to any of the aforegoing in this clause 13.3 above under the laws of any
                                         jurisdiction occurs in respect of such other party; provided that in the case that any
                                         such order or act is initiated by any third party, the right of termination shall apply
                                         only if such order or act as aforesaid is not cancelled within [***] of the grant of
                                         such order or the performance of such act. Notwithstanding the foregoing, any delay in
                                         payment by the Company of no more than [***], occurring no more than [***] per year,
                                         caused by a corresponding delay in receiving payment from a Sublicensee, which occurs
                                         in the ordinary course of business, shall not be grounds for termination by Yeda pursuant
                                         to this clause 13.4.

 

    - 48 -

     

    

 

		13.5.	Upon
                                         the termination of this Agreement for whatever reason, except for the termination of
                                         this Agreement due to the passage of time: (i) all rights in and to the Licensed
                                         Information and the Yeda Patents and Yeda’s rights in the Subsequent Results and the
                                         Joint Patents shall revert to Yeda and the Company shall not be entitled to make any
                                         further use thereof and the Company shall deliver to Yeda all drawings, plans, diagrams,
                                         specifications, other documentation, models or any other physical matter in the Company’s
                                         possession in any way containing, representing or embodying the Licensed Information;
                                         and (ii) the Company shall grant to Yeda a non-exclusive, irrevocable, perpetual,
                                         fully paid-up, sublicenseable, worldwide licence in respect of the Company’s rights in
                                         the Subsequent Results and the Company’s Information (subject, if required, to
                                         the consent of the Incubators Committee and/or to Yeda’s undertaking to comply with any
                                         regulatory obligations and to assume any royalty obligations in respect thereof). In
                                         this clause 13.5, the term “the Company’s Information”
                                         shall mean any invention, product, material, method, process, technique, know-how, data,
                                         information or other result which does not form part of the Licensed Information, the
                                         Initial Research Results or the Subsequent Results, discovered or occurring in the course
                                         of or arising from the performance by the Company of the development work pursuant to
                                         clause 8 above, including any regulatory filing or approval, filed or obtained by
                                         the Company in respect of WIS Products and Group I Products (including any Companion
                                         Diagnostic Kits of any WIS Products or Group 1 Products, all communications with the
                                         regulatory authorities, the drug master file and any data, information or document covered
                                         by data protection or data exclusivity. Yeda shall bear all out-of-pocket costs reasonably
                                         incurred by the Company in order to comply with the provisions of this clause 13.5. For
                                         the avoidance of doubt, nothing in the foregoing shall be construed as an obligation
                                         on the part of the Company to deliver to Yeda any physical matter relating to Group 2
                                         Company Products or to any Other Products.

 

    - 49 -

     

    

 

		13.6.	In
                                         the event that this Agreement shall be terminated, other than by way of termination by
                                         Yeda pursuant to clause 13.4 above, and that Yeda shall grant to a third party a licence
                                         in respect of the Subsequent Results, the Joint Patents and/or the Company’s Information
                                         (either without or together with the Licensed Information and the Yeda Patents) and Yeda
                                         shall receive in respect of such licence consideration, then, subject to the Company
                                         having complied and continuing to comply with all its obligations under this Agreement
                                         which remain in existence following termination of this Agreement as aforesaid, Yeda
                                         shall pay to the Company an amount equal to [***] of the Net Proceeds actually received
                                         by Yeda in respect of such a licence to Company Products and [***] of the Net Proceeds
                                         actually received by Yeda in consideration of such a licence to WIS Products, until such
                                         time as the Company shall have received, in aggregate, an amount equal to (i) [***] the
                                         amount invested by the Company (not including grants funding and any payments made to
                                         Yeda hereunder or to the Scientists under any consultancy agreement for research into
                                         Group 1 Products) in the development of the Products included within the scope of such
                                         licences and (ii) the amount of any obligations of the Company to repay or pay royalties
                                         in respect of grants awarded for the development of any Products incorporating such Subsequent
                                         Results, Joint Patents and/or Company’s Information included within the scope of such
                                         licences, but only to the extent such obligations are not assumed by Yeda. The provisions
                                         of clauses 9.3 through 9.5 shall apply with respect to payments to the Company in respect
                                         of Net Proceeds, mutatis mutandis.

 

For
the purpose of this clause 13.6, “Net Proceeds” means any consideration actually received by Yeda in respect
of such licence in cash or in kind (excluding funds or grants for research and/or development at the Institute or payments for
the supply of services) after deduction of all costs, fees and expenses incurred by Yeda in connection with such licence (including,
without limitation, patent related costs, and all attorneys’ fees and expenses and other costs and expenses in connection with
the negotiation, conclusion and administration of such licence).

 

		13.7.	The
                                         termination of this Agreement for any reason shall not relieve the Company of any obligations
                                         which shall have accrued prior to such termination.

 

    - 50 -

     

    

 

		14.	EQUITY

 

		14.1.	The
                                         Company will, on the date of signature of this Agreement, issue to Yeda, in consideration
                                         for their nominal value, a number of ordinary shares of the Company, representing, immediately
                                         after the issue thereof, [***] of the Company’s issued and outstanding share capital
                                         of the Company, on a Fully Diluted Basis (“Yeda’s Shares”),
                                         as per the cap table attached hereto as Appendix H. The rights to be attached
                                         to Yeda’s Shares will be identical to those rights attached to any ordinary shares
                                         in the Company issued or transferred to the incorporating shareholders of the Company.
                                         In this clause 14, “Fully Diluted Basis” shall mean, after taking
                                         into account all issued and outstanding share capital of the Company, all securities
                                         issuable upon the conversion of any then-existing convertible securities or loans, the
                                         exercise of all outstanding warrants or options and any other right granted to any third
                                         party to receive shares in the Company, as if all such matters had been converted or
                                         exercised, as applicable. For the avoidance of doubt, commitments by the shareholders
                                         to invest further funds in the Company against receipt of preferred shares of nominal
                                         value NIS 0.01 each of the Company (the “Preferred Shares”), beyond
                                         the Ordinary Share Investment (defined below) shall not be taken into account for the
                                         purpose of calculating the Fully Diluted Basis. [REINSTATED]

		14.2.	The
                                         Company undertakes that Yeda’s percentage ownership of the Company as aforesaid will
                                         not be diluted by grants from the OCS which are invested in the Company within the framework
                                         of the biotechnological incubator operated by FutuRx pursuant to Directive 8.22 of the
                                         Director General of the Israeli Ministry of Economy (“FutuRx Investment Amount”)
                                         or by investments in the Company by way of irredeemable ordinary share capital, including
                                         ordinary share capital invested by way of matching funds to the FutuRx Investment Amount
                                         as required under the terms of the OCS grants (the “Ordinary Share Investment”),
                                         in the aggregate amount of [***].

 

		14.3.	Upon
                                         expiry of the Incubator Period, in the event that the sum of the FutuRx Investment Amount
                                         and the Ordinary Share Investment shall equal or exceed [***] in aggregate, then no further
                                         shares of the Company shall be issued to Yeda. To the extent that such sum shall be less
                                         than [***] in aggregate, then the Company shall issue to Yeda further fully-paid up ordinary
                                         shares in the Company as per the formula shown in Appendix I attached hereto.

 

		14.4.	Yeda
                                         shall be entitled, free of any restriction, whether in the Company’s articles of association
                                         or otherwise, to transfer any or all of the Shares to the Institute or to any scientist,
                                         employee or any other person entitled to receive shares under the rules of the Institute
                                         or to a trust created for the benefit of any of the aforementioned persons (all such
                                         entities “Permitted Transferees”). 

 

    - 51 -

     

    

 

		14.5.	In
                                         the event that the Company shall propose at any time to issue (any such proposed issue
                                         a “Share Issue”) any shares therein or other securities convertible
                                         into shares of any class or nature (“Additional Shares”), Yeda shall
                                         have the same right as afforded to the incorporating shareholders of the Company or contractually
                                         granted thereto, to participate in such Share Issue pro rata to Yeda’s then percentage
                                         shareholding in the Company, on the same terms and conditions as are offered to other
                                         prospective acquirers of Additional Shares in each such Share Issue (such right a “Right
                                         of Participation”), all in accordance with the articles of association of the
                                         Company.

 

		14.6.	Yeda
                                         shall be entitled, by written notice to the Company, to assign, at any time any particular
                                         Right of Participation, in whole or in part, or all Rights of Participation, to one or
                                         more Permitted Transferees or to Osage University Partners. Any Participation Notice
                                         confirming participation in a Share Issue shall further indicate whether the relevant
                                         Right of Participation is being exercised by Yeda, by Permitted Transferees, by Osage
                                         University Partners or a combination thereof.

 

		14.7.	The
                                         provisions of clauses 14.3 to 14.6 shall survive the termination of this Agreement.

 

		15.	Exit
                                         FEE

 

In
the event of any M&A Transaction (as defined in the Company’s articles of association), including: (i) a merger of the Company
with or into another entity; or (ii) the sale of substantially all of the Company’s shares or assets (any of the aforegoing an
“Exit”), the Company confirms and undertakes that Yeda shall, in addition to any entitlement as a shareholder
of the Company, within [***] of the closing of the relevant Exit, receive from the Company an amount equal to 1% (one per cent)
of the total consideration (of whatever kind) received by the Company’s shareholders as a result of the Exit, following, where
relevant, the payment of all deemed liquidation preferences.

 

For
the avoidance of doubt, in the event of an Exit, Yeda shall not be entitled to any share in the consideration received in connection
therewith other than the Exit Fee and the proceeds of the sale of any shares issued to Yeda as referred to in clause 14 above.

 

    - 52 -

     

    

 

		16.	Notices

 

Any
notice or other communication required to be given by one party to the other under this Agreement shall be in writing and shall
be deemed to have been served: (i) if personally delivered, when actually delivered; or (ii) if sent by facsimile, the
next business day after receipt of confirmation of transmission; or (iii) 10 (ten) days after being mailed by certified or
registered mail, postage prepaid (for the purposes of proving such service—it being sufficient to prove that such notice
was properly addressed and posted) to the respective addresses of the parties set out below, or to such other address or addresses
as any of the parties hereto may from time to time in writing designate to the other party hereto pursuant to this clause 16:

 

		16.1.	to Yeda at:	P.O. Box 95

Rehovot 76100

Israel

		Attention:	the
CEO

		Facsimile:	(08)
9470739

 

		16.2.	to the Company at:	2 Ilan Ramon Street, Science Park

Ness Ziona 7403635

Israel

		Attention:	the
CEO

		Facsimile:	(08)
9553111

 

with
a copy that will not

	 	constitute
notice to:	Pearl
Cohen Zedek Latzer Baratz

1
Azrieli Centre,

Round
Tower, 18th floor

Tel-Aviv
6702101

Attention:
[***]

Facsimile:
(03) 6073778

 

		17.	Value
                                         Added Tax

 

The
Company shall pay to Yeda all amounts of Value Added Tax imposed on Yeda in connection with the transactions under this Agreement.
All amounts referred to in this Agreement shall be exclusive of Value Added Tax.

 

    - 53 -

     

    

 

		18.	Governing
                                         law and jurisdiction

 

This
Agreement shall be governed in all respects by the laws of Israel and the parties hereby submit to the exclusive jurisdiction
of the competent Israeli courts, except that Yeda may bring suit against the Company in any other jurisdiction outside Israel
in which the Company has assets or a place of business.

 

		19.	Miscellaneous

 

		19.1.	The
                                         headings in this Agreement are intended solely for convenience or reference and shall
                                         be given no effect in the interpretation of this Agreement.

 

		19.2.	This
                                         Agreement constitutes the entire agreement between the parties hereto in respect of the
                                         subject-matter hereof, and supersedes all prior agreements or understandings between
                                         the parties relating to the subject-matter hereof (including the Memorandum of Understanding
                                         between Yeda and the Company dated 30 September 2014) and this Agreement may be amended
                                         only by a written document signed by both parties hereto. No party has, in entering into
                                         this Agreement, relied on any warranty, representation or undertaking, except as may
                                         be expressly set out herein.

 

		19.3.	This
                                         Agreement may be executed in any number of counterparts (including counterparts transmitted
                                         by telecopier or fax), each of which shall be deemed to be an original, but all of which
                                         taken together shall be deemed to constitute one and the same instrument.

 

		19.4.	No
                                         waiver by any party hereto, whether express or implied, of its rights under any provision
                                         of this Agreement shall constitute a waiver of such party’s rights under such provisions
                                         at any other time or a waiver of such party’s rights under any other provision of this
                                         Agreement. No failure by any party hereto to take any action against any breach of this
                                         Agreement or default by another party hereto shall constitute a waiver of the former
                                         party’s rights to enforce any provision of this Agreement or to take action against such
                                         breach or default or any subsequent breach or default by such other party.

 

    - 54 -

     

    

 

		19.5.	If
                                         any provision of this Agreement is held to be unenforceable under applicable law, then
                                         such provision shall be modified as set out below and the balance of this Agreement shall
                                         be interpreted as if such provision were so modified and shall be enforceable in accordance
                                         with its terms. The parties shall negotiate in good faith in order to agree on the terms
                                         of an alternative provision which complies with applicable law and achieves, to the greatest
                                         extent possible, the same effect as would have been achieved by the invalid or unenforceable
                                         provision.

 

		19.6.	Nothing
                                         contained in this Agreement shall be construed to place the parties in a relationship
                                         of partners or parties to a joint venture or to constitute either party an agent, employee
                                         or a legal representative of the other party and neither party shall have power or authority
                                         to act on behalf of the other party or to bind the other party in any manner whatsoever.

 

		19.7.	Any
                                         amount payable hereunder by one of the parties to the other that has not been paid by
                                         its due date of payment shall bear interest from its due date of payment until the date
                                         of actual payment, at the rate of the lower of [***] or the highest rate permitted under
                                         applicable law or pro rata for part thereof.

 

		19.8.	All
                                         payments to be made to Yeda hereunder shall be made in US Dollars or in Euros by banker’s
                                         cheque or by bank transfer to Yeda’s bank account, the details of which are as
                                         follows: Bank Leumi le–Israel B.M., Rehovot business branch, 2 Ilan Ramon Street,
                                         Ness Ziona, branch #[***], account no. [***]; swift: [***], Routing Number: [***], IBAN
                                         no. [***].

 

		19.9.	All
                                         payments to be made to Yeda hereunder shall be made free and clear of, and without any
                                         deduction for or on account of, any set-off, counterclaim or tax.

 

		19.10.	Each
                                         party agrees to execute, acknowledge and deliver such further documents and instruments
                                         and do any other acts, from time to time, as may be reasonably necessary, to effectuate
                                         the purposes of this Agreement.

 

		19.11.	None
                                         of the provisions of this Agreement shall be for the benefit of, or enforceable by, any
                                         person who is not a party to this Agreement, save for clauses 10 and 12 above.

 

    - 55 -

     

    

 

IN
WITNESS WHEREOF the parties hereto have set their signatures as of this 22 day of June 2015.

 

	for	YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED	 	for	MBCURE LTD.
	 	 	 	 	 
	Signature: 	/s/
    Prof. Mudi Sheves	 	Signature: 	/s/
    Dr. Naomi Zak
	Name	Prof.
    Mudi Sheves	 	Name:	Dr.
    Naomi Zak
	Title	Chairman	 	Title:	CEO
	 	 	 	 	 
	 	 	 	Signature: 	/s/
    Dr. Einat Zisman
	 	 	 	Name:	Dr.
    Einat Zisman
	 	 	 	Title:	Director

 

List
of Appendices:

 

		A	Existing
Know-How

		B	The
Research Budget

		C	The
Research Program

		D	Letter
of Instructions/Power of Attorney

		E	MTA

		F	Initial
Development Program

		G	Approved
Text

		H	Capitalization
Table

		I	Yeda
Anti-Dilution Calculation

 

    - 56 -

     

    

 

Appendix
D

Letter
of Instructions - Patent Counsel

 

Date:

To:

 

The
undersigned, on its own behalf and, as applicable, on behalf of its permitted successors and/or assigns, hereby empowers, authorises,
directs and instructs you, to:

 

release
the Power of Attorney attached hereto as Annex 1 (the “POA”) to Yeda Research and Development Company Limited
and/or, as applicable, its respective successors and/or assigns (“Yeda”), upon Yeda’s first demand to you in
writing to such effect (the “Demand”); and

 

act
upon and in accordance with Yeda’s other instructions as may be included in the Demand and/or in any other writing issued to you
by Yeda.

 

You
shall hold the POA in escrow pending your receipt of the Demand or Yeda’s other instructions as aforesaid, and upon and as from
your receipt of the Demand or Yeda’s other instructions as aforesaid, you shall act solely in accordance therewith, and in no
other manner. Without limiting the foregoing, you shall not be entitled to act upon the demand and/or instructions of any person
or entity, other than Yeda.

 

Yeda
shall be deemed a third party beneficiary of this Letter of Instructions.

 

This
Letter of Instructions and any of its terms are irrevocable and unconditional on the part of the undersigned and, as applicable,
on the part of the undersigned’s permitted successors and/or assigns.

 

IN
WITNESS WHEREOF, the undersigned has executed this Letter of Instructions as of the date hereof, by its duly authorized representatives:

 

	 	 
	MBCure LTD.	 
	 	 
	By: 	           	 
	Name: 	 	 
	Title: 	 	 
	 	 
	Agreed and accepted,	 
	 	 
	 	 

 

    - 57 -

     

    

 

Annex
1

 

Power
of Attorney

 

Date:

 

To:
Yeda Research and Development Company Ltd.

 

The
undersigned, on its own behalf and, as applicable, on behalf of its permitted successors and/or assigns, hereby empowers and authorises
Yeda Research and Development Company Ltd. and/or, as applicable, its respective successors and/or assigns (“Yeda”)
and/or any of Yeda’s officers, and appoints Yeda and/or any of Yeda’s officers as the undersigned’s attorney-in-fact, to
execute any document and/or instrument including without limitation any deeds of assignment and patent forms and perform any other
acts, all on behalf of the undersigned and on behalf of its permitted successors and/or assigns, as Yeda may deem necessary or
appropriate for purposes of the assignment to Yeda of the undersigned’s part interest in the Yeda Patents (as such term is defined
in the Research and Licence Agreement by and between MBCure LTD. and Yeda of June 22, 2015).

 

This
Power of Attorney and any of its terms are worldwide, and this Power of Attorney is given for the benefit of a third party, and
since a third party’s rights are dependent upon the validity of this power of attorney, it is irrevocable and unconditional on
the part of the undersigned and, as applicable, on the part of the undersigned’s permitted successors and/or assigns.

 

IN
WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of the date hereof, by its duly authorised representatives:

 

	 	 
	MBCure Ltd.	 
	 	 
	By: 	           	 
	Name: 	 	 
	Title: 	 	 

 

    - 58 -

     

    

 

Appendix
I

[***]

 

[***]

 

 

-
59 -Exhibit
10.6

 

Pursuant
to Item 601(B)(10) of Regulation S-K, certain portions of this exhibit have been redacted and, where applicable, have been marked
“[***],” such redactions are immaterial and would be competitively harmful if publicly disclosed.

 

 

 

 

 

 

 

 

 

 

 

 

 MASSACHUSETTS
INSTITUTE OF TECHNOLOGY

 

 

EXCLUSIVE
PATENT LICENSE AGREEMENT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

TABLE
OF CONTENTS

 

	TABLE OF CONTENTS	ii
	R E C I T A L S	1
	1. Definitions.	2
	2. Grant of Rights.	7
	3. COMPANY Diligence Obligations.	10
	4. Royalties and Payment Terms.	12
	5. Reports and Records.	16
	6. Patent Prosecution.	18
	7. Infringement.	20
	8. Indemnification and Insurance.	22
	9. Representations AND Warranties.	23
	10. Assignment.	24
	11. General Compliance with Laws	24
	12. Termination.	25
	13. Dispute Resolution.	27
	14. Miscellaneous.	29
	APPENDIX A	33
	APPENDIX B	34
	EXHIBIT A	35

 

    ii

     

    

 

MASSACHUSETTS
INSTITUTE OF TECHNOLOGY

EXCLUSIVE
PATENT LICENSE AGREEMENT

 

This
Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is
between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office
at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and MBcure Ltd. (“COMPANY”), a company formed under the laws
of Israel, having its principal office at 2 Ilan Ramon, Ness Ziona, Israel.

 

R
E C I T A L S

 

WHEREAS,
M.I.T. is the owner of certain PATENT RIGHTS (as later defined herein) relating [***] and has the right to grant licenses under
said PATENT RIGHTS;

 

WHEREAS,
Timothy Kuan-Ta Lu, an inventor of the PATENT RIGHTS and current employee of M.I.T., has or will shortly acquire equity in COMPANY,
the Conflict Avoidance Statement of inventor name is attached as Exhibit A hereto;

 

WHEREAS,
M.I.T. desires to have the PATENT RIGHTS developed and commercialized to benefit the public and is willing to grant a license
thereunder;

 

WHEREAS,
COMPANY has represented to M.I.T., to induce M.I.T. to enter into this Agreement, that COMPANY shall commit itself to a diligent
program of exploiting the PATENT RIGHTS so that public utilization shall result therefrom; and

 

WHEREAS,
COMPANY desires to obtain a license under the PATENT RIGHTS upon the terms and conditions hereinafter set forth.

 

NOW,
THEREFORE, M.I.T. and COMPANY hereby agree as follows:

 

1.
Definitions.

 

1.1
“AFFILIATE” shall mean any legal entity (including, but not limited to, a corporation, partnership, or limited
liability company) that is controlled by COMPANY. For the purposes of this definition, the term “control” means (i)
beneficial ownership of at least fifty percent (50%) of the voting securities of a corporation or other business organization
with voting securities or (ii) a fifty percent (50%) or greater interest in the net assets or profits of a partnership or other
business organization without voting securities.

 

     

     

    

 

1.2
“COVERED MATERIAL” shall mean any active ingredient for use in the Field that, in whole or in part:

 

(i) absent
the license granted hereunder, would infringe one or more valid claims of the PATENT RIGHTS; or

 

(ii) is
manufactured using a LICENSED PROCESS or that, when used, practices a LICENSED PROCESS; and/or

 

(iii)
 contains an IDENTIFIED PRODUCT

 

1.3
“FIELD” shall mean (a) the treatment, prevention or diagnosis of any disease or condition within the labeled
indications: [***] and (b) the treatment, prevention or diagnosis of any other human disease or condition by specifically targeting
any of the following: [***].

 

COMPANY
may request, from time to time, the inclusion of one or more additional bacteria to the FIELD; if MIT has not granted an exclusive
license with respect to such requested bacteria that would prevent the inclusion of such bacteria in the license, the parties
will negotiate in good faith the possibility of including such additional bacteria to the FIELD.

 

1.4
“IDENTIFIED PRODUCT” shall mean any product that in whole or in part is created, developed, discovered, identified
or selected by the use of LICENSED PROCESS(ES) by the COMPANY or AFFILIATES or SUBLICENSEES. Notwithstanding the foregoing, any
IDENTIFIED PRODUCT that also falls within the definition of LICENSED PRODUCT shall still be deemed a LICENSED PRODUCT for the
purposes of the AGREEMENT and COMPANY shall make all payments due for a LICENSED PRODUCT

 

1.5
“IMPROVEMENT” shall mean any patentable or potentially patentable invention that:

 

(i)
is made under an M.I.T. research program in the laboratory of Timothy Kuan-Ta Lu as the Principal Investigator (“Principal
Investigator”);

 

(ii)
is disclosed to the M.I.T. Technology Licensing Officer within [***] of the EFFECTIVE DATE;

 

(iii)
is dominated by claims of the PATENT RIGHTS licensed under this Agreement and listed in Appendix A as of the EFFECTIVE DATE; and

 

    2

     

    

 

(iv)
is available for licensing after satisfaction of any obligations to third parties, including without limitation sponsors of the
research leading to such invention.

 

1.6
“LICENSED PRODUCT” shall mean any product that, in whole or in part:

 

(i) absent
the license granted hereunder, would infringe one or more valid claims of the PATENT RIGHTS; or

 

(ii) is
manufactured by using a LICENSED PROCESS or that, when used, practices a LICENSED PROCESS.

 

1.7
“LICENSED PROCESS” shall mean any process the practice of which, absent the license granted hereunder, would
infringe one or more valid claims of the PATENT RIGHTS or which uses a LICENSED PRODUCT.

 

1.8
“NET SALES” shall mean the gross amount billed by COMPANY and its AFFILIATES and SUBLICENSEES for LICENSED
PRODUCTS, IDENTIFIED PRODUCTS, and LICENSED PROCESSES, less the following:

 

(i)
customary trade, quantity, or cash discounts to the extent actually allowed and taken;

 

(ii)
amounts repaid or credited by reason of rejection or return;

 

(iii)
portions of invoiced amounts written off by COMPANY or its AFFILIATES as uncollectable (if such amounts are subsequently collected,
they will be deemed NET SALES in the quarter in which they are collected); and

 

(iv)
to the extent separately stated on purchase orders, invoices, or other documents of sale, any taxes or other governmental charges
levied on the production, sale, transportation, delivery, or use of a LICENSED PRODUCT, IDENTIFIED PRODUCT or LICENSED PROCESS
which is paid by or on behalf of COMPANY, its AFFILIATE or a SUBLICENSEE; and

 

(v)
outbound transportation (including packaging, freight, shipping and insurance) costs if separately stated on the invoice.

 

No
deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed
by COMPANY and on its payroll, or for cost of collections. NET SALES shall occur on the date of billing for a LICENSED PRODUCT,
IDENTIFIED PRODUCT or LICENSED PROCESS. If a LICENSED PRODUCT, IDENTIFIED PRODUCT or a LICENSED PROCESS is distributed at a discounted
price that is substantially lower than the customary price charged by COMPANY for sales to similarly situated customers (e.g.
customers of similar size, buying power and/or strategic value in the same or similar territory, taking into consideration factors
such as government imposed pricing and local pricing of therapeutics) or distributed for non-monetary consideration (whether or
not at a discount), NET SALES shall be calculated based on the average price (the average price is not calculated using sale prices
of LICENSED PRODUCTS, IDENTIFIED PRODUCTS or LICENSED PROCESSES that are substantially lower than customary price or that are
distributed for non-monetary consideration) of the same LICENSED PRODUCT, IDENTIFIED PRODUCT or LICENSED PROCESS charged to an
independent third party in the same territory during the same REPORTING PERIOD or, in the absence of such sales, on the fair market
value of the LICENSED PRODUCT, IDENTIFIED PRODUCTS or LICENSED PROCESS.

 

    3

     

    

 

Non-monetary
consideration shall not be accepted by COMPANY, any AFFILIATE, or any SUBLICENSEE for any LICENSED PRODUCTS, IDENTIFIED PRODUCTS
or LICENSED PROCESSES without the prior written consent of M.I.T.

 

If
a LICENSED PRODUCT or IDENTIFIED PRODUCT is sold in any country in the form of a combination product containing one or more active
ingredients in addition to the Covered Material (“Combination Product”), [***]. If, in a specific country, the Covered
Material or the other active ingredient(s) is not sold separately, a market price for the Covered Material and the other active
ingredient(s) in the Combination Product shall be determined by Company in good faith and in accord with generally accepted accounting
practices. If MIT disagrees with the market price attributed by Company to the Covered Material and/or other active ingredient(s)
in the Combination Product as set forth in any royalty report provided by Company to MIT, MIT will be entitled to notify Company
in writing of such disagreement within [***] of receipt of the relevant report and the parties will resolve such disagreement
in accordance with the following “baseball arbitration” procedure:

 

(a)
If MIT notifies Company of any disagreement with respect to the market price values attributed by Company to any priced components
of any Combination Product as set forth in a royalty report provided by Company pursuant to Section 5.2 (“Attributed Market
Price”), executive officers of each of the parties shall meet within [***] of such notice to negotiate in good faith and
agree on such Attributed Market Prices provided, however, that Company shall provide, in advance of such meeting, and to MIT’s
reasonable satisfaction, detailed written information sufficient for such executive offices to understand the full rationale for
Company’s Attributed Market Price. If the dispute has not been resolved within [***] after the commencement of such meeting
or if meeting has not commenced within [***] after MIT’s notice of disagreement, then either Party may initiate a demand
for arbitration under the International Chamber of Commerce Rules of Arbitration as then in effect and, except as set forth herein,
the dispute will be arbitrated in accordance with such rules. The arbitration shall be final and binding.

 

(b)
The arbitration shall be conducted before a panel of [***] arbitrators, each (i) with significant expertise and experience in
the marketing and sale of products in the field of the Combination Product and (ii) not then nor previously employed by either
party or any of their respective Affiliates, nor (unless agreed otherwise by the parties) serving or having served as a consultant
of either of the parties and/or their respective Affiliates. The arbitration shall be held in a mutually agreeable location or,
if the parties cannot agree upon a location within [***] after the arbitrator panel has been constituted, at a location deemed
fair to the Parties by the arbitrators. The arbitration shall be conducted in English.

 

    4

     

    

 

(d)
Within [***] after the selection of the arbitration panel, each party shall submit to the arbitrators and exchange with each other
its arguments regarding the Attributed Market Price at issue.

 

(e)
Within [***] after the date of the delivery to the arbitrator(s) of such arguments by the parties, the arbitrator(s) shall deliver
its/their decision to the parties by facsimile and electronic transmission. The arbitrator shall be limited to awarding only one
or the other of the two figures submitted. The decision of the arbitrator(s) shall be determinative with respect to the Attributed
Market Price at issue.

 

(f)
Each Party shall bear the costs of its own counsel fees and expenses and half of the costs of the arbitration, unless the arbitrators
determine that the non-prevailing Party should bear more of the costs and expenses. Judgment upon an award rendered by the arbitrators
may be entered by any court having jurisdiction thereof.

 

However,
provided that in the case the Combination Product is sold under a Sublicense agreement and the other active ingredient(s) included
in such Combination Product are not ingredient(s) licensed by Company nor its Affiliates to the Sublicensee, the market price
attributed by Company to the Covered Material and the other active ingredient(s) in the Combination Product will be deemed to
be fair market price if they are the same as the prices attributed to the Covered Material and the other active ingredient(s)
in the Combination Product under the Sublicense agreement.

 

Notwithstanding
the above, “Net Sales” shall not include: (i) the provision of LICENSED PRODUCTS or IDENTIFIED PRODUCTS by COMPANY,
its AFFILIATES or SUBLICENSEES for use in clinical trials or compassionate treatment or the distribution of LICENSED PRODUCTS
or IDENTIFIED PRODUCTS through a not-for-profit foundation to eligible patients provided that COMPANY, its AFFILIATE or SUBLICENSEE,
as applicable, receives no consideration from such clinical trials or not-for-profit foundation for such use of LICENSED PRODUCTS
or IDENTIFIED PRODUCTS and (ii) LICENSED PRODUCTS or IDENTIFIED PRODUCTS provided as samples to promote additional Net Sales or
for test marketing purposes, in amounts consistent with normal business practices of COMPANY, its AFFILITATES or SUBLICENSEES,
provided that COMPANY, its AFFILIATE or SUBLICENSEE, as applicable, receives no consideration for such samples.

 

1.9
“PATENT CHALLENGE” shall mean the commencement of a legal action or administrative proceeding challenging the
validity or patentability and/or non-infringement of any of the PATENT RIGHTS (as defined below) or otherwise seeking to invalidate
any of the PATENT RIGHTS.

 

    5

     

    

 

1.10
“PATENT RIGHTS” shall mean:

 

(a)
the United States and international patents listed on Appendix A;

 

(b)
the United States and international patent applications and/or provisional applications listed on Appendix A and the
resulting patents;

 

(c)
any patent applications resulting from the provisional applications listed on Appendix A, and any divisionals, continuations,
continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the
patent applications listed on Appendix A and of such patent applications that result from the provisional applications
listed on Appendix A, to the extent the claims are directed to subject matter specifically described in the patent applications
listed on Appendix A and the resulting patents;

 

(d)
any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the patents
described in (a), (b), and (c) above; and

 

(e)
international (non-United States) patent applications and provisional applications filed after the EFFECTIVE DATE claiming priority
to any of the applications described above and the relevant international equivalents to divisionals, continuations, continuation-in-part
applications and continued prosecution applications of such patent applications to the extent the claims are directed to subject
matter specifically described in the patents or patent applications referred to in (a), (b), (c), and (d) above, and the resulting
patents.

 

1.11
“REPORTING PERIOD” shall begin on the first day of each [***] and end on the last day of such [***].

 

1.12
“RESEARCH SUPPORT PAYMENTS” shall mean payments to COMPANY or an AFFILIATE from a SUBLICENSEE or corporate
partner that are expressly intended only to fund or pay for (i) the purchase or use of equipment, supplies, products or services,
or (ii) the use of employees and/or consultants, to achieve a bona fide research or development goal for the commercialization
of LICENSED PRODUCTS, IDENTIFIED PRODUCTS, or LICENSED PROCESSES, as indicated by their inclusion as specific line items in a
written agreement between COMPANY or AFFILIATE and the SUBLICENSEE or corporate partner.

 

1.13
“SUBLICENSE INCOME” shall mean any payments that COMPANY or an AFFILIATE receives from a SUBLICENSEE in consideration
of the sublicense of the rights granted COMPANY and AFFILIATES under Section 2.1, including without limitation license fees, milestone
and bonus payments, option payments, license maintenance fees, and other payments, but specifically excluding royalties
on NET SALES payable under Sections 4.1(d) and 4.1(e). For clarity, SUBLICENSE INCOME specifically excludes: (a) reimbursement
of the patent expenses paid by COMPANY to MIT; (b) RESEARCH SUPPORT PAYMENTS; (c) equity investments at fair market value (excluding
premiums paid as consideration for the sublicense); and (d) amounts received from a SUBLICENSEE in connection with a bona fide,
fully repayable, market rate loan made by SUBLICENSEE to Company (unless such loans are forgiven prior to complete repayment).

 

    6

     

    

 

1.14
“SUBLICENSEE” shall mean any non-AFFILIATE sublicensee of the rights granted COMPANY under Section 2.1.

 

1.15
“TERM” shall mean the term of this Agreement, which shall commence on the EFFECTIVE DATE and shall remain in
effect until the expiration or abandonment of all issued patents and filed patent applications within the PATENT RIGHTS, unless
earlier terminated in accordance with the provisions of this Agreement.

 

1.16
“TERRITORY” shall mean world-wide.

 

2.
Grant of Rights.

 

2.1
License Grants. Subject to the terms of this Agreement, including without limitation Section 2.5, M.I.T. hereby grants
to COMPANY and its AFFILIATES for the TERM an exclusive, royalty-bearing license under the PATENT RIGHTS to develop, have developed,
make, have made, use, have used, sell, have sold, offer to sell, lease, import and have imported LICENSED PRODUCTS and IDENTIFIED
PRODUCTS in the FIELD in the TERRITORY and to develop and perform LICENSED PROCESSES for use in the FIELD in the TERRITORY.

 

2.3
Sublicenses.

 

(a)
So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD, COMPANY shall have the right to grant sublicenses
of its rights under Section 2.1; SUBLICENSEES shall not have the right to grant sublicenses, without the prior written approval
of MIT who will have the sole discretion. COMPANY shall incorporate terms and conditions into its sublicense agreements sufficient
to enable COMPANY to comply with this Agreement. COMPANY shall also include provisions in all sublicenses to provide that in the
event that SUBLICENSEE brings a PATENT CHALLENGE against M.I.T. or assists another party in bringing a PATENT CHALLENGE against
M.I.T. (except as required under a court order or subpoena) then COMPANY may terminate the sublicense.

 

    7

     

    

 

(b)
COMPANY shall promptly furnish M.I.T. with a fully signed photocopy of any sublicense agreement; provided that COMPANY may redact
from such copies any information COMPANY or the SUBLICENSEE deems confidential information of the parties thereto, and to the
extent that it does not impair M.I.T.’s ability to ensure compliance with this Agreement.

 

(c)
Upon termination of this Agreement for any reason, any direct SUBLICENSEE of COMPANY not then in material breach of the sublicense
agreement shall have the right to obtain, upon notice to M.I.T. within [***] of termination of this Agreement, a license directly
from M.I.T. on substantially similar terms and conditions as set forth herein. M.I.T. shall not be obligated to grant to any such
SUBLICENSEE any rights under the PATENT RIGHTS that are broader than the rights previously granted by COMPANY to such SUBLICENSEE,
or inconsistent with the rights granted to COMPANY under this Agreement. Each such SUBLICENSEE shall be deemed a third party beneficiary
for purposes of this Section 2.3. 

 

2.4
U.S. Manufacturing. As applicable to this Agreement, COMPANY agrees to comply with the requirements of 35 U.S.C. §
204 “Preference for United States Industry”, as amended, or any successor statutes or regulations.

 

2.5
Retained Rights.

 

(a)
Research and Educational Use. M.I.T. retains the right on behalf of itself and all other non-profit research institutions
to practice under the PATENT RIGHTS for academic research, teaching, and educational purposes.

 

(b)
Federal Government. COMPANY acknowledges that the U.S. federal government retains a royalty-free, non-exclusive, non-transferable
license to practice any government-funded invention claimed in any PATENT RIGHTS as set forth in 35 U.S.C. §§ 201-211,
and the regulations promulgated thereunder, as amended, or any successor statutes or regulations.

 

    8

     

    

 

2.6
Option to Improvements. To the extent that an IMPROVEMENT is available for licensing, and subject to the consent of M.I.T.’s
Principal Investigator, M.I.T. hereby grants to COMPANY a first option (the “OPTION”) to add M.I.T.’s interest
in such IMPROVEMENT to this Agreement, by amendment, in accordance with this Section 2.6. Promptly after the M.I.T. Technology
Licensing Office receives disclosure of an IMPROVEMENT, the M.I.T. Technology Licensing Office shall notify COMPANY in writing
of the IMPROVEMENT, furnishing COMPANY a copy of the invention disclosure and/or any related patent application(s). Such invention
disclosure and any related patent application(s) shall be kept confidential by COMPANY. Notwithstanding the foregoing, M.I.T.
shall be under no obligation to file patent applications for any IMPROVEMENT unless COMPANY exercises its OPTION with respect
to such IMPROVEMENT. COMPANY may exercise its OPTION to obtain a license to patent rights on such IMPROVEMENT by notifying M.I.T.
thereof in writing within [***] after M.I.T.’s notice of such IMPROVEMENT (the “OPTION PERIOD”). If COMPANY
does not exercise its OPTION within the OPTION PERIOD, COMPANY’s rights under this Section 2.6 shall expire and M.I.T. shall
be free to license such IMPROVEMENT to any third party. For each OPTION so exercised, COMPANY will pay M.I.T. an Improvement Addition
Fee of [***] (the “Improvement Addition Fee”), and shall be responsible for the payment of fees and costs relating
to the filing, prosecution and maintenance of the patent rights covering such IMPROVEMENT, subject to Section 6.4. Upon COMPANY’S
exercise of such right and payment of the Improvement Addition Fee, the parties shall amend this Agreement to add the patent application(s)
covering such IMPROVEMENT under applicable terms and conditions.

  

2.7.
No Additional Rights. Except as set forth in Section 2.6, nothing in this Agreement shall be construed to confer any rights
upon COMPANY by implication, estoppel, or otherwise as to any technology or patent rights of M.I.T. or any other entity other
than the PATENT RIGHTS, regardless of whether such technology or patent rights shall be dominant or subordinate to any PATENT
RIGHTS.

 

    9

     

    

 

3.
COMPANY Diligence Obligations.

 

3.1
Diligence Requirements. COMPANY shall use commercially reasonable diligent efforts, alone and/or through its AFFILIATES
and/or SUBLICENSEES, to develop LICENSED PRODUCTS and/or IDENTIFIED PRODUCTS and to introduce LICENSED PRODUCTS and/or IDENTIFIED
PRODUCTS into the commercial market; thereafter, COMPANY alone and/or through its AFFILIATES and/or Sublicensees, shall use reasonable
efforts to make LICENSED PRODUCTS and/or IDENTIFIED PRODUCTS reasonably available to the relevant patient population. Specifically,
COMPANY or AFFILIATE shall fulfill the following obligations:

 

(a)
Within [***] after the EFFECTIVE DATE, COMPANY shall furnish M.I.T. with a written research and development plan describing the
major tasks to be achieved in order to bring to market a LICENSED PRODUCT and/or IDENTIFIED PRODUCT, specifying the number of
staff and other resources to be devoted to such research and development effort.

 

(b)
Within [***] after the end of each calendar year, COMPANY shall furnish M.I.T. with a written report (consistent with Section
5.1(a)) on the progress of its efforts during the immediately preceding calendar year to develop and (when applicable) commercialize
LICENSED PRODUCTS, IDENTIFIED PRODUCTS, or LICENSED PROCESSES. The report shall also contain a discussion of intended efforts
for the year in which the report is submitted.

 

(c)
COMPANY or an AFFILIATE or SUBLICENSEE shall develop a candidate of a LICENSED PRODUCT or IDENTIFIED PRODUCT and test such candidate
in a pre-clinical proof of concept study (demonstration of efficacy in lysing the target bacteria under an in vitro and
model animal setting) on or before the [***] of the EFFECTIVE DATE. Upon successful completion of such proof of concept, the relevant
candidate will be designated as a “Candidate Product” and within [***] of such a designation, COMPANY will notify
M.I.T. in writing.

 

(d)
COMPANY and/or AFFILIATES shall permit an in-plant inspection by M.I.T. on or before [***], and thereafter permit in-plant inspections
by M.I.T. at regular intervals with at least [***] between each such inspection.

 

(e)
COMPANY, alone or together with its AFFILIATES and/or SUBLICENSEE(s), shall expend at least the amounts set forth below on research
and/or development of LICENSED PRODUCTS and/or IDENTIFIED PRODUCTS in each calendar year (pro-rated for partial years) and ending
with the first commercial sale of a LICENSED PRODUCT or IDENTIFIED PRODUCT:

 

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

 

(f)
By the [***] of the [***], COMPANY or an AFFILIATE or SUBLICENSEE shall [***] with a LICENSED PRODUCT or IDENTIFIED PRODUCT [***].

 

    10

     

    

 

(g)
By the [***] of the [***], COMPANY or an AFFILIATE or SUBLICENSEE shall [***] with a LICENSED PRODUCT or IDENTIFIED PRODUCT.

 

(h)
By the [***] of the [***], COMPANY or an AFFILIATE or SUBLICENSEE shall [***] for a LICENSED PRODUCT or IDENTIFIED PRODUCT.

 

(i)
By the [***] of the [***], COMPANY or an AFFILIATE or SUBLICENSEE shall [***] for a LICENSED PRODUCT or IDENTIFIED PRODUCT and
shall [***] LICENSED PRODUCTS and/or IDENTIFIED PRODUCTS.

 

(j)
By the [***] of the [***], COMPANY or an AFFILIATE or SUBLICENSEE shall [***] of a LICENSED PRODUCT or IDENTIFIED PRODUCT.

 

(k)
By the [***] of the [***], COMPANY or an AFFILIATE or SUBLICENSEE shall [***] for a [***] LICENSED PRODUCT or IDENTIFIED PRODUCT
in the [***].

 

In
the event that M.I.T. reasonably determines that COMPANY (together with its AFFILIATES and SUBLICENSEES) has failed to fulfill
any of its obligations under this Section 3.1, then M.I.T. may treat such failure as a material breach in accordance with Section
12.3(b), subject to the applicable cure periods therein. Notwithstanding the foregoing, in the event that COMPANY anticipates
a failure to meet an obligation in any of Sections 3.1(f)-(k) due to unexpected technical, adverse events or regulatory difficulties,
COMPANY will promptly advise M.I.T. in writing, and representatives of each party will meet to review the reasons for anticipated
failure and discuss in good faith a potential revision to the diligence schedule. COMPANY and M.I.T. will enter into a written
amendment to this Agreement with respect to any mutually agreed upon change(s) to the relevant obligation(s). Any such future
changes to these diligence obligations that would extend the first commercial sale of the first LICENSED PRODUCT or IDENTIFIED
PRODUCT past [***] post the date of [***] would be subject to [***] extension fee of [***].

 

M.I.T.
will not terminate the Agreement for COMPANY’s failure to meet its diligence obligations found in sections 3.1 (f-j) if
LICENSED PRODUCTS or IDENTIFIED PRODUCTS have entered the clinical phase. However, M.I.T. at its sole discretion, may remove from
the FIELD the subfield ([***]) that COMPANY is failing to meet its diligence obligations for as defined in sections 3.1 (g) or
3.1 (k) (“NON-DILIGENT FIELD”), except with respect to LICENSED PRODUCTS or IDENTIFIED PRODUCTS in such field that
entered the clinical phase and any COVERED MATERIAL included in such products, and all of COMPANY’s and its AFFILIATE’s
rights in the NON-DILIGENT FIELD shall terminate except with respect to such LICENSED PRODUCTS or IDENTIFIED PRODUCTS in such
subfield that entered the clinical phase and any COVERED MATERIAL included in such products. The removal of the NON-DILIGENT FIELD
will not affect the remaining terms of this Agreement or COMPANY’s rights with respect to LICENSED PRODUCTS or IDENTIFIED
PRODUCTS in such field that entered the clinical phase and any COVERED MATERIAL included in such products. 

 

    11

     

    

 

4.
Royalties and Payment Terms.

 

4.1
Consideration for Grant of Rights.

 

(a)
License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to M.I.T. within [***] of the EFFECTIVE DATE a license
issue fee of twenty-five thousand dollars ($25,000), and, in accordance with Section 6.3, [***]. These payments are nonrefundable.

 

(b)
License Maintenance Fees. COMPANY shall pay to M.I.T. the following license maintenance fees on the dates set forth below:

 

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

 

This
annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to running royalties subsequently
due on NET SALES earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties due
in such calendar year shall not be creditable to amounts due for future years.

 

    12

     

    

 

(c)
Milestone Payments. COMPANY shall pay to M.I.T. the following payments within [***] following the achievement of the relevant
Milestone Event set forth below for each LICENSED PRODUCT or IDENTIFIED PRODUCT (for clarity, two or more products that contain
the same COVERED MATERIAL will be deemed the same LICENSED PRODUCT or IDENTIFIED PRODUCT), regardless of whether such milestone
is achieved by COMPANY or by an AFFILIATE or a SUBLICENSEE:

 

	Milestone
    Event	 	Payment
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

 

If
COMPANY receives a payment constituting SUBLICENSE INCOME that is directly attributable to the occurrence of a Milestone Event
or circumstance substantially equivalent to such Milestone Event and COMPANY has paid or is obligated to pay to M.I.T. its due
share of such payment under the clause entitled “Sublicense Income”), such payment on account of such SUBLICENSE INCOME
shall be fully creditable against the Milestone Payment due to MIT such that M.I.T. shall receive either the total value of its
due share of SUBLICENSE INCOME only or it’s due share of the Milestone Payment only, whichever is greater, but not the sum
of both amounts.

 

Furthermore,
in the case of any future changes to the diligence obligations in Section 3.1 that would extend the first commercial sale of the
first LICENSED PRODUCT past [***] post the date of first designation of a Candidate Product, and if the COMPANY has not paid [***]
of the milestones payments in Section 4.1 (c) at least [***], or in the instance that a IDENTIFIED PRODUCT is being carried forward
instead of a LICENSED PRODUCT and in recognition of the value of the PATENT RIGHTS and the time it takes to bring LICENSED PRODUCTS
to market, COMPANY agrees that COMPANY’s obligation to pay these milestone payments with respect to the first LICENSED PRODUCT
or IDENTIFIED PRODUCT to reach the relevant milestone shall survive expiration of all issued patents and filed patent applications
within the PATENT RIGHTS (“Surviving Milestone Obligations”). In addition this obligation to pay Surviving Milestone
Obligations shall survive termination of the AGREEMENT as specified in Section 12.6(a).

 

    13

     

    

 

(d)
Running Royalties for LICENSED PRODUCTS. COMPANY shall pay to M.I.T. running royalties for LICENSED PRODUCT(S) on annual
Net Sales, as follows:

 

	●	[***]
                                         royalties on the [***] of NET SALES of LICENSED PRODUCT(S) in the relevant calendar year;

	●	[***]
                                         royalties on the next [***] NET SALES of LICENSED PRODUCT(S) in the relevant calendar
                                         year (i.e. the portion of such NET SALES in such calendar year [***].

	●	[***]
                                         royalties on Net Sales of such LICENSED PRODUCT(S) [***] (i.e. the portion of such NET
                                         SALES in such calendar year [***]).

 

(e)
Running Royalties for IDENTIFIED PRODUCTS. COMPANY shall pay to M.I.T. running royalties for IDENTIFIED PRODUCT(S) on annual
Net Sales, as follows:

 

	●	[***]
                                         royalties on the [***] of NET SALES of IDENTIFIED PRODUCT(S) in the relevant calendar
                                         year;

	●	[***]
                                         royalties on the next [***] NET SALES of IDENTIFIED PRODUCT(S) in the relevant calendar
                                         year (i.e. the portion of such NET SALES in such calendar year [***]).

	●	[***]
                                         royalties on Net Sales of such IDENTIFIED PRODUCT(S) [***] (i.e. the portion of such
                                         NET SALES in such calendar year [***]).

 

For
the convenience of the parties, in recognition of the value of the PATENT RIGHTS and LICENSED PROCESSES in identifying IDENTIFIED
PRODUCTS, and in the time it takes to bring IDENTIFIED PRODUCTS to market, COMPANY agrees to pay royalties under this Section
on each IDENTIFIED PRODUCT for [***] after first commercial sale of such IDENTIFIED PRODUCT in the first country in which it is
sold. For clarity, two or more products that contain the same COVERED MATERIAL will be deemed the same IDENTIFIED PRODUCT and
the royalties will be due for a period of [***] from the first commercial sale of the first such IDENTIFIED PRODUCT. The obligation
to pay running royalties on each IDENTIFIED PRODUCT shall survive termination of the AGREEMENT as specified in Section 12.6(a).

 

Running
Royalties shall be payable for each REPORTING PERIOD and shall be due to M.I.T. within [***] of the end of each REPORTING PERIOD.

 

(f)
Sharing of SUBLICENSE INCOME. COMPANY shall pay M.I.T. the following percentage on SUBLICENSE INCOME received by COMPANY
or AFFILIATES:

 

	(i)	[***]
                                         if the sublicense agreement, under which such SUBLICENSE INCOME is paid, is signed [***]
                                         in Company reaches [***];

	(ii)	[***]
                                         if the sublicense agreement, under which such SUBLICENSE INCOME is paid, is signed [***]
                                         in Company reaches [***];

	(iii)	[***]
                                         if the sublicense agreement, under which such SUBLICENSE INCOME is paid, is signed [***]
                                         in Company reach [***].

 

    14

     

    

 

Such
amount shall be payable for each REPORTING PERIOD and shall be due to M.I.T. within [***] of the end of each REPORTING PERIOD.

 

(g)
Consequences of a PATENT CHALLENGE. In the event that (i) COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against
M.I.T., or (ii) COMPANY or any of its AFFILIATES assists another party in bringing a PATENT CHALLENGE against M.I.T. (except as
required under a court order or subpoena), and (iii) M.I.T. does not choose to exercise its rights to terminate this Agreement
pursuant to Section 12.4, then the running royalties due hereunder shall be [***] for the remainder of the term of the AGREEMENT.
In the event that such a PATENT CHALLENGE is successful, COMPANY will have no right to recoup any royalties paid during the period
of challenge. In the event that a PATENT CHALLENGE is unsuccessful, COMPANY shall reimburse M.I.T. for all reasonable legal fees
and expenses incurred in its defense against the PATENT CHALLENGE.

 

(h)
No Multiple Royalties. If the manufacture, use, lease, or sale of any LICENSED PRODUCT or the performance of any LICENSED
PROCESS is covered by more than one of the PATENT RIGHTS, multiple royalties shall not be due.

 

(i)
Royalty Offset. In the event that COMPANY is contractually or by court decision required to make royalty payments to one
or more third parties in order to design, discover, develop, make, use, or sell LICENSED PRODUCTS or IDENTIFIED PRODUCTS, COMPANY
may offset a total of [***] of such third-party payments against any royalty payments that are due to M.I.T. in the same REPORTING
PERIOD, provided, however, that in no event shall the royalty payments under Sections 4.1 (d) or 4.1 (e) when aggregated with
any other offsets and credits allowed under this Agreement, be less than [***] of NET SALES for LICENSED PRODUCT(S) or [***] of
NET SALES of IDENTIFIED PRODUCT(S) in any REPORTING PERIOD.

 

4.2
Payments.

 

(a)
Method of Payment. All payments under this Agreement should be made payable to “Massachusetts Institute of Technology”
and sent to the address identified in Section 14.1. Each payment should reference this Agreement and identify the obligation
under this Agreement that the payment satisfies.

 

    15

     

    

 

(b)
Payments in U.S. Dollars. All payments due under this Agreement shall be payable in United States dollars. Conversion of
foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported by the Federal
Reserve Bank of St. Louis) on the last working day of the calendar quarter of the applicable REPORTING PERIOD. Such payments shall
be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar
taxes or other government imposed fees or taxes, except as permitted in the definition of NET SALES. MIT will cooperate with COMPANY
to provide such information and records as COMPANY may require in connection with any application to the tax authorities in any
country, including attempt to obtain an exemption or a credit for any withholding tax due in any country on account of the payments
made by COMPANY to MIT hereunder.

 

(c)
Late Payments. Any payments by COMPANY that are not paid on or before the date such payments are due under this Agreement
shall bear interest, to the extent permitted by law, at [***] of interest as reported by the Federal Reserve Bank of St. Louis
on the last business day of the calendar quarterly reporting period to which such royalty payments relate.

 

5.
Reports and Records.

 

5.1
Frequency of Reports.

 

(a)
Before First Commercial Sale. Prior to the first commercial sale of any LICENSED PRODUCT or first commercial performance
of any LICENSED PROCESS, COMPANY shall deliver reports to M.I.T. annually, within [***] of the end of each calendar year, containing
information concerning the immediately preceding calendar year, as described in Section 3.1(b).

 

(b)
Upon First Commercial Sale of a LICENSED PRODUCT or IDENTIFIED PRODUCT. COMPANY shall report to M.I.T. the date of first
commercial sale of a LICENSED PRODUCT or IDENTIFIED PRODUCT within [***] of occurrence in each country.

 

    16

     

    

 

(c)
After First Commercial Sale. After the first commercial sale of a LICENSED PRODUCT or IDENTIFIED PRODUCT, COMPANY shall
deliver reports to M.I.T. within [***] of the end of each REPORTING PERIOD, containing information concerning the immediately
preceding REPORTING PERIOD, as further described in Section 5.2.

 

5.2
Content of Reports and Payments. Each report delivered by COMPANY to M.I.T. shall contain at least the following information
for the immediately preceding REPORTING PERIOD:

 

(i)
the number of LICENSED PRODUCTS and/or IDENTIFIED PRODUCTS relevant to the calculation of NET SALES sold, leased or distributed
by COMPANY, its AFFILIATES and SUBLICENSEES to independent third parties in each country, and, if applicable, the number of LICENSED
PRODUCTS and/or IDENTIFIED PRODUCTS used by COMPANY, its AFFILIATES and SUBLICENSEES in the provision of services for a fee in
each country;

 

(ii)
the gross amount charged by COMPANY, its AFFILIATES and SUBLICENSEES for LICENSED PRODUCTS and/or IDENTIFIED PRODUCTS;

 

(iii)
with respect to each unique Combination Product sold, the price values assigned to A and B, as used to determine the proration
factor with respect to NET SALES of Combination Products (for the avoidance of doubt, M.I.T. hereby retains the right to request
and receive any documentation used by COMPANY and or its consultants and advisors to determine such values, specifically without
the need to invoke the procedures outlined in Section 5.4, below);

 

(iv)
calculation of NET SALES for the applicable REPORTING PERIOD in each country, including a listing of applicable deductions;

 

(v)
total royalty payable on NET SALES in U.S. dollars, together with the exchange rates used for conversion;

 

(vi)
the amount of SUBLICENSE INCOME received by COMPANY from each SUBLICENSEE and the amount due to M.I.T. from such SUBLICENSE INCOME,
including an itemized breakdown of the sources of income comprising the SUBLICENSE INCOME; and

 

If
no amounts are due to M.I.T. for any REPORTING PERIOD, the report shall so state.

 

    17

     

    

 

5.3
Financial Statements. Within [***] of the Company’s receipt of its audited financial statements for a given year
or by [***], whichever comes first, COMPANY shall provide M.I.T. with a copy of such audited financial statements.

 

5.4
Records. COMPANY shall maintain, and shall cause its AFFILIATES and shall ensure that its SUBLICENSEES undertake to maintain,
complete and accurate records relating to LICENSED PRODUCTS and IDENTIFIED PRODUCTS developed, made, sold, leased or distributed
by COMPANY, its AFFILIATES and SUBLICENSEES and SUBLICENSE INCOME received which records shall contain sufficient information
to permit M.I.T. to confirm the accuracy of any reports delivered to M.I.T. under Section 5 and compliance in other respects with
this Agreement. The relevant party shall retain such records for at least [***] following the end of the calendar year to which
they pertain, during which time M.I.T., shall have the right, at M.I.T.’s expense, to cause an independent, certified public
accountant inspect such records during normal business hours to verify any reports and payments made or compliance in other respects
under this Agreement; provided in each case, that such accountant signs a confidentiality and non-use agreement in a form acceptable
to COMPANY, in its reasonable discretion. The foregoing notwithstanding, the auditor shall have sole discretion to determine the
scope of information required to effect the review required by this section, and such scope shall not be subject to approval by
COMPANY. In the event that any audit performed under this Section reveals an underpayment in excess of [***], COMPANY shall bear
the full cost of such audit and shall remit any amounts due to M.I.T. within [***] of receiving notice thereof from M.I.T. The
parties agree that all applicable statutes of limitation and time-based defenses (including, but not limited to, estoppel and
laches) shall be tolled upon any request by M.I.T. for an audit under this Section. The parties shall cooperate in taking any
actions necessary to achieve this result.

 

6.
Patent Prosecution.

 

6.1
Responsibility for PATENT RIGHTS. M.I.T. shall prepare, file, prosecute, and maintain all of the PATENT RIGHTS using patent
counsel reasonably acceptable to COMPANY. COMPANY shall have reasonable opportunities to advise M.I.T. and shall cooperate with
M.I.T. in such filing, prosecution, and maintenance. M.I.T. shall instruct its patent counsel to copy COMPANY on all patent prosecution
documents relating to the PATENT RIGHTS and shall provide COMPANY a reasonable opportunity to review and comment on such materials.
M.I.T. shall consider in good faith any comments received from COMPANY relating to prosecution and maintenance of the PATENT RIGHTS

 

    18

     

    

 

6.2
International (non-United States) Filings. Appendix B is a list of countries in which patent applications corresponding
to the United States patent applications listed in Appendix A shall be filed, prosecuted, and maintained. Appendix B
may be amended by mutual agreement of COMPANY and M.I.T.

 

6.3
Payment of Expenses. Subject to Section 6.4, payment of all documented, out-of-pocket fees and costs, including attorneys’
fees, relating to the filing, prosecution, and maintenance of the PATENT RIGHTS (“Patent Expenses”) shall be the responsibility
of COMPANY and other commercial licensees of the PATENT RIGHTS as they exist from time to time (as used herein a “Commercial
Licensee” shall mean a for-profit entity that has been granted a license by M.I.T. under the PATENT RIGHTS to develop and
sell products). Subject to Section 6.4, COMPANY shall be responsible for a pro rata share of all Patent Expenses, whether such
amounts were incurred before or after the EFFECTIVE DATE. As of the EFFECTIVE DATE, COMPANY’s pro rata share is [***] of
the total, and M.I.T. has incurred approximately [***] for such patent-related fees and costs, with respect to which M.I.T. will
provide COMPANY with supporting documentation. As commercial licensees are added over time, COMPANY’s pro rata share will
decrease on a going forward basis only. No credits shall be allowed for payments due prior to each new commercial licensee. COMPANY
shall reimburse [***] of all patent costs incurred prior to the EFFECTIVE DATE, that have not already been reimbursed, within
thirty days of the EFFECTIVE DATE. COMPANY will reimburse the remaining [***] within [***] of the EFFECTIVE DATE of this Agreement
or immediately upon termination of this Agreement if this Agreement is terminated prior to the [***] of this Agreement as long
as there are no additional commercial licensees prior to these dates. If there are additional Commercial Licensees then COMPANY
will not have to pay this remaining [***]. COMPANY will be responsible for its pro rata share for all patent expenses incurred
after the EFFECTIVE DATE. COMPANY shall reimburse all amounts due pursuant to this Section within [***] of invoicing, supported
by appropriate documentation; late payments shall accrue interest at [***]. In all instances, M.I.T. shall pay the fees prescribed
for large entities to the United States Patent and Trademark Office. Subject to Section 6.4, payment of all fees and costs, including
attorneys’ fees, relating to the filing, prosecution and maintenance of the PATENT RIGHTS (including without limitation
interferences, reexaminations and reissues) shall be the responsibility of COMPANY, whether such amounts were incurred before
or after the EFFECTIVE DATE subject to the terms agreed upon in this section.

 

    19

     

    

 

6.4.
Abandonment. Notwithstanding the above, in the event that COMPANY desires to discontinue its support of any patent or patent
application within the PATENT RIGHTS, in any particular country or countries, COMPANY shall provide M.I.T. with at least [***]
prior written notice of such intended discontinuance of support. In such event, (i) any such patent or patent application, on
a country by country basis, (the “RETURNED RIGHTS”) shall be removed from the definition of PATENT RIGHTS under this
Agreement, (ii) the licenses granted to COMPANY and its AFFILIATES as to such RETURNED RIGHTS shall terminate, and (iii) COMPANY
shall have no further obligation with respect to such RETURNED RIGHTS pursuant to Section 6.3, M.I.T. shall have the unrestricted
right to license such RETURNED RIGHTS to third parties. Such notice to discontinue its support of any patent or patent application
shall not relieve COMPANY from the obligations to pay for costs with respect to the filing, prosecution, and maintenance of such
PATENT RIGHTS incurred prior to the expiration of the [***] notice period.

 

7.
Infringement.

 

7.1
Notification of Infringement. Each party agrees to provide written notice to the other party promptly after becoming aware
of any infringement of the PATENT RIGHTS in the FIELD.

 

7.2
Right to Prosecute Infringements.

 

(a)
COMPANY Right to Prosecute. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in the
TERRITORY, COMPANY, to the extent permitted by law, shall have the right, under its own control and at its own expense, to prosecute
any third party infringement of the PATENT RIGHTS in the FIELD in the TERRITORY, subject to Sections 7.4 and 7.5. If required
by law, M.I.T. shall permit any action under this Section to be brought in its name, including being joined as a party-plaintiff,
provided that COMPANY shall hold M.I.T. harmless from, and indemnify M.I.T. against, any costs, expenses, or liability that M.I.T.
incurs in connection with such action.

 

Prior
to commencing any such action, COMPANY shall consult with M.I.T. and shall consider the views of M.I.T. regarding the advisability
of the proposed action and its effect on the public interest. COMPANY shall not enter into any settlement, consent judgment, or
other voluntary final disposition of any infringement action under this Section that will adversely affect the validity, enforceability
or scope of the PATENT RIGHTS, without the prior written consent of M.I.T, which consent shall not be unreasonably withheld or
delayed.

 

    20

     

    

 

(b)
M.I.T. Right to Prosecute. In the event that COMPANY fails to have initiated an infringement action within a reasonable
time after COMPANY first becomes aware of the basis for such action (and provided that the Company has been unsuccessful in persuading
the alleged infringer to desist), M.I.T. shall have the right, at its sole discretion, to prosecute such infringement under its
sole control and at its sole expense, and any recovery obtained shall belong to M.I.T.

 

7.3
Declaratory Judgment Actions. In the event that a PATENT CHALLENGE is brought against M.I.T. or COMPANY by a third party,
M.I.T., at its option, shall have the right within [***] after commencement of such action to take over the sole defense of the
action at its own expense. If M.I.T. does not exercise this right, COMPANY may take over the sole defense of the action at COMPANY’s
sole expense, subject to Sections 7.4 and 7.5.

 

7.4
Offsets. COMPANY may offset a total of [***] of any expenses incurred under Sections 7.2 and 7.3 against any payments due
to M.I.T. under Article 4, provided that in no event shall such payments under Article 4, when aggregated with any other offsets
and credits allowed under this Agreement, be reduced by more than [***] in any REPORTING PERIOD.

 

7.5
Recovery. Any recovery obtained in an action brought by COMPANY under Sections 7.2 or 7.3 shall be distributed as
follows: (i) each party shall be reimbursed for any expenses incurred in the action (including the amount of any royalty or other
payments withheld from M.I.T. as described in Section 7.4), (ii) as to ordinary damages, COMPANY shall receive an amount equal
to its lost profits or a reasonable royalty on the infringing sales, or whichever measure of damages the court shall have applied,
and COMPANY shall pay to M.I.T. based upon such amount a reasonable approximation of the royalties and other amounts that COMPANY
would have paid to M.I.T. if COMPANY had sold the infringing products, processes and services rather than the infringer, and (iii)
as to special or punitive damages, the parties shall share equally in any award.

 

7.6
Cooperation. Each party agrees to cooperate in any action under this Article which is controlled by the other party, provided
that the controlling party reimburses the cooperating party promptly for any out-of-pocket costs and expenses incurred by the
cooperating party in connection with providing such assistance.

 

7.7
Right to Sublicense. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in the TERRITORY,
COMPANY shall have the sole right to sublicense any alleged infringer in the FIELD in the TERRITORY for future use of the PATENT
RIGHTS in accordance with the terms and conditions of this Agreement relating to sublicenses. Any revenues to COMPANY pursuant
to such sublicense shall be treated as set forth in Article 4.

 

    21

     

    

 

8.
Indemnification and Insurance.

 

8.1
Indemnification.

 

(a)
Indemnity. COMPANY shall indemnify, defend, and hold harmless M.I.T. and its trustees, officers, faculty, students, employees,
and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage,
loss, or expense (including reasonable attorneys’ fees and expenses) incurred by or imposed upon any of the Indemnitees
as a result of any third party claims, suits, actions, demands or judgments resulting from the exercise of any rights granted
to COMPANY under this Agreement or any breach of this Agreement by COMPANY, except in each case to the extent caused by the gross
negligence or willful misconduct of M.I.T.

 

(b)
Procedures. The Indemnitees agree to provide COMPANY with prompt written notice of any claim, suit, action, demand, or
judgment for which indemnification is sought under this Agreement. COMPANY agrees, at its own expense, to provide attorneys reasonably
acceptable to M.I.T. to defend against any such claim. The Indemnitees shall cooperate fully with COMPANY in such defense and
will permit COMPANY to conduct and control such defense and the disposition of such claim, suit, or action (including all decisions
relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall have the right to retain its own
counsel, at the expense of COMPANY, if representation of such Indemnitee by the counsel retained by COMPANY would be inappropriate
because of actual conflicts in the interests of such Indemnitee and any other party represented by such counsel. COMPANY agrees
to keep M.I.T. informed of the progress in the defense and disposition of such claim and to consult with M.I.T. with regard to
any proposed settlement.

 

8.2
Insurance. COMPANY shall obtain and carry in full force and effect commercial general liability insurance, and at the time
as COMPANY commences clinical trials with respect to LICENSED PRODUCTS or IDENTIFIED PRODUCTS will carry products/completed operations
coverage and errors and omissions liability insurance which shall protect COMPANY and Indemnitees with respect to events covered
by Section 8.1(a) above. Such insurance (i) shall be issued by an insurer pre-approved by M.I.T., such approval not to be
unreasonably withheld, (ii) shall list M.I.T. as an additional insured thereunder, for the commercial general liability policy
only, and (ii) shall require [***] written notice to be given to M.I.T. prior to any cancellation or material change thereof.
The limits of the commercial general liability insurance shall not be less than [***] with an aggregate of [***] for bodily injury
including death, property damage, and products/completed operations coverage. The limits of the errors and omissions liability
insurance shall not be less than [***]. At M.I.T.’s request, from time to time, COMPANY shall provide M.I.T. with Certificates
of Insurance evidencing ongoing compliance with this Section. COMPANY shall continue to maintain such insurance after the expiration
or termination of this Agreement during any period in which COMPANY or any AFFILIATE or SUBLICENSEE continues (i) to make, use,
or sell a product that was a LICENSED PRODUCT under this Agreement or (ii) to perform a service that was a LICENSED PROCESS under
this Agreement, and thereafter for a period of [***], if the coverage is under a claims-made policy.

 

    22

     

    

 

9.
Representations AND Warranties.

 

9.1
M.I.T. hereby represents and warrants that, as of the EFFECTIVE DATE of this Agreement (a) all named inventors of the PATENT RIGHTS
have duly executed instruments assigning their entire right, title and interest in the PATENT RIGHTS to M.I.T. as assignee; (b)
to its knowledge there is no action, suit, proceeding or investigation pending or threatened against M.I.T. that challenges the
right of M.I.T. to enter into this Agreement, or to consummate the transactions contemplated hereby; (c) M.I.T. has the authority
to grant the licenses as granted herein; and (d) M.I.T. has not granted to any third party any rights under the PATENT RIGHTS
that would conflict with this Agreement.

 

9.2
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T. MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING
THE PATENT RIGHTS AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF M.I.T. OR THIRD PARTIES,
VALIDITY, ENFORCEABILITY AND SCOPE OF PATENT RIGHTS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER
OR NOT DISCOVERABLE.

 

9.3
Neither Party will be responsible to the other for incidental or consequential damages of any kind, including economic damages
or injury to property and lost profits regardless of whether such damages arise from claims based upon contract, negligence, tort
(including strict liability or other legal theory), a breach of any warranty or term of this Agreement, and regardless of whether
it was advised or had reason to know of the possibility of incurring such damages in advance.

 

    23

     

    

 

10.
Assignment.

 

This
Agreement is personal to COMPANY and no rights or obligations may be assigned by Company without the prior written consent of
M.I.T., which consent shall not be unreasonably withheld, except that COMPANY may assign its rights and obligations under this
Agreement without such a consent to an AFFILIATE or another successor corporation in connection with the merger, consolidation,
or sale (with or to such corporation) of all or substantially all of its assets or that portion of its business to which this
Agreement relates; provided, however , that(i) any payment amounts due to M.I.T. (including royalties and all patent expense amounts
owed to M.I.T. under this Agreement, that are actually due as of the effective date of such assignment) shall be received by M.I.T.
in full within [***] of any such transaction; and (ii) such successor shall agree in writing to be bound by the terms and conditions
of this Agreement on or before the effective date of such transaction. Any assignment purported or attempted to be made in violation
of the terms of this Section shall be null and void and of no legal effect.

 

11.
General Compliance with Laws

 

11.1
Compliance with Laws. COMPANY shall use reasonable commercial efforts to comply with all commercially material applicable
local, state, federal, and international laws and regulations relating to the development, manufacture, use, and sale of LICENSED
PRODUCTS and LICENSED PROCESSES under this Agreement.

 

11.2
Export Control. COMPANY and its AFFILIATES and SUBLICENSEES shall comply with all United States laws and regulations controlling
the export of certain commodities and technical data, including without limitation all Export Administration Regulations of the
United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the export
of certain types of commodities and technical data to specified countries. COMPANY hereby gives written assurance that it will
comply with, and will cause its AFFILIATES and will ensure that its SUBLICENSEES undertake to comply with, all United States export
control laws and regulations, that as between COMPANY and M.I.T. it bears sole responsibility for any violation of such laws and
regulations by itself or its AFFILIATES or SUBLICENSEES, and that it will indemnify, defend, and hold M.I.T. harmless (in accordance
with Section 8.1) for the consequences of any such violation.

 

    24

     

    

 

11.3
Non-Use of M.I.T. Name. COMPANY and its AFFILIATES and SUBLICENSEES shall not use the name of “Massachusetts Institute
of Technology,” “Lincoln Laboratory” or any variation, adaptation, or abbreviation thereof, or of any of its
trustees, officers, faculty, students, employees, or agents, or any trademark owned by M.I.T., or any terms of this Agreement
in any promotional material or other public announcement or disclosure relating to this Agreement without the prior written consent
of M.I.T, which consent M.I.T. may withhold in its sole discretion.  The foregoing notwithstanding, without the consent of
M.I.T., COMPANY may make factual statements during the term of this Agreement that COMPANY has a license from M.I.T. under one
or more of the patents and/or patent applications comprising the PATENT RIGHTS in business literature and public announcements.
Such statements may not be used in marketing, promotion, or advertising.

 

11.4
Marking of LICENSED PRODUCTS and IDENTIFIED PRODUCTS. To the extent commercially feasible and consistent with prevailing
business practices, COMPANY shall mark, and shall cause its AFFILIATES and ensure that its SUBLICENSEES undertake to mark, all
LICENSED PRODUCTS and IDENTIFIED PRODUCTS that are sold under this Agreement in countries in which there are issued patents within
the PATENT RIGHTS with the number of each issued patent under the PATENT RIGHTS that applies to such LICENSED PRODUCT.

 

12.
Termination.

 

12.1
Voluntary Termination by COMPANY. COMPANY shall have the right to terminate this Agreement, for any reason, (i) upon at
least ninety (90) days prior written notice to M.I.T., such notice to state the date at least ninety (90) days in the future upon
which termination is to be effective, and (ii) upon payment of all amounts due to M.I.T. through such termination effective date.

 

12.2
Cessation of Business. If COMPANY ceases to carry on its business related to this Agreement, M.I.T. shall have the right
to terminate this Agreement immediately upon written notice to COMPANY.

 

    25

     

    

 

12.3
Termination for Default.

 

(a)
Nonpayment. In the event COMPANY fails to pay any amounts due and payable to M.I.T. hereunder, and fails to make such payments
within [***] after receiving written notice of such failure, M.I.T. may terminate this Agreement immediately upon written notice
to COMPANY.

 

(b)
Material Breach. If either party commits a material breach of its obligations under this Agreement, except for breach as
described in Section 12.3(a), and fails to cure that breach within [***] after receiving written notice thereof from the other
party, the non-breaching party may terminate this Agreement immediately upon written notice to COMPANY.

 

12.4
Termination as a Consequence of Patent Challenge.

 

 (a) By
COMPANY. If COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against M.I.T., or assists or causes others to bring
a PATENT CHALLENGE against M.I.T. (except as required under a court order or subpoena), then M.I.T. may immediately terminate
this Agreement.

 

 (b) By
SUBLICENSEE. If a SUBLICENSEE brings a PATENT CHALLENGE or assists another party in bringing a PATENT CHALLENGE (except as
required under a court order or subpoena), then M.I.T. may send a written demand to COMPANY to terminate such sublicense. If COMPANY
fails to so terminate such sublicense [***] after M.I.T.’s demand, M.I.T. may immediately terminate this Agreement.

 

12.5
Disputes regarding Termination. If COMPANY disputes any termination by M.I.T. under this Section, it must notify M.I.T.
of the nature of such dispute and the proposed manner in which to resolve the dispute within [***] of receipt of certified notification
of termination by M.I.T., whichever is sooner. If the parties do not resolve such dispute within [***] of such notification, then
COMPANY shall be required to initiate the dispute resolution procedures outlined in Section 13.3(a) immediately. If it does not
do so, COMPANY shall be considered to have waived its rights to dispute the termination.

 

    26

     

    

 

12.6
Effect of Termination.

 

(a)
Survival. The following provisions shall survive the expiration or termination of this Agreement:

 

		●	Article
                                         1 (“Definitions”);

		●	Article
                                         8 (“Indemnification and Insurance”); 

		●	Article
                                         9 (“Representations and Warranties”);

		●	Article
                                         13 (“Dispute Resolution”); 

		●	Article
                                         14 (“Miscellaneous”); 

		●	The
                                         last paragraph of Section 4.1(c) (“Milestone Payments”), solely with respect
                                         to Surviving Milestone Payments

		●	Section
                                         4.1 (e) (Running Royalties for IDENTIFIED PRODUCTS)

		●	Section
                                         5.2 (“Content of Reports and Payments”) with respect to sales of LICENSED
                                         PRODUCTS made and SUBLICENSE INCOME received prior to termination; 

		●	Section
                                         5.4 (“Records”); 

		●	Section
                                         11.1 (“Compliance With Laws”);

		●	Section
                                         11.2 (“Export Control”);

		●	Section
                                         12.5 (“Disputes regarding Termination”); and

		●	Section
                                         12.6 (“Effect of Termination”).

 

(b)
Pre-termination Obligations. In no event shall termination of this Agreement release COMPANY from the obligation to pay
any amounts that became due on or before the effective date of termination.

 

13.
Dispute Resolution.

 

13.1
Mandatory Procedures. The parties agree that any dispute arising out of or relating to this Agreement shall be resolved
solely by means of the procedures set forth in this Article, and that such procedures constitute legally binding obligations that
are an essential provision of this Agreement. If either party fails to observe the procedures of this Article, as may be modified
by their written agreement, the other party may bring an action for specific performance of these procedures in any court of competent
jurisdiction.

 

    27

     

    

 

13.2
Equitable Remedies. Although the procedures specified in this Article are the sole and exclusive procedures for the resolution
of disputes arising out of or relating to this Agreement, either party may seek a preliminary injunction or other provisional
equitable relief if, in its reasonable judgment, such action is necessary to avoid irreparable harm to itself or to preserve its
rights under this Agreement.

 

13.3
Dispute Resolution Procedures.

 

(a)
Mediation. In the event of any dispute arising out of or relating to this Agreement, either party may initiate mediation
upon written notice to the other party (“Notice Date”) pursuant to Section 14.1, whereupon both parties shall be obligated
to engage in a mediation proceeding. The mediation shall commence within [***] of the Notice Date. The mediation shall be conducted
by a single mediator in Boston, Massachusetts. The party requesting mediation shall designate two (2) or more nominees for mediator
in its notice. The other party may accept one of the nominees or may designate its own nominees by notice addressed to the American
Arbitration Association (AAA) and copied to the requesting party. If within, [***] following the request for mediation, the parties
have not selected a mutually acceptable mediator, a mediator shall be appointed by the AAA according to the Commercial Mediation
Rules. The mediator shall attempt to facilitate a negotiated settlement of the dispute, but shall have no authority to impose
any settlement terms on the parties. The expenses of the mediation shall be borne equally by the parties, but each party shall
be responsible for its own counsel fees and expenses.

 

(b)
Trial Without Jury. If the dispute is not resolved by mediation within [***] after commencement of mediation, each party
shall have the right to pursue any other remedies legally available to resolve the dispute, provided, however, that the parties
expressly waive any right to a jury trial in any legal proceeding under this Article.

 

13.4
Performance to Continue. Each party shall continue to perform its undisputed obligations under this Agreement pending final
resolution of any dispute arising out of or relating to this Agreement; provided, however, that a party may suspend performance
of its undisputed obligations during any period in which the other party fails or refuses to perform its undisputed obligations.
Nothing in this Article is intended to relieve COMPANY from its obligation to make undisputed payments pursuant to Articles 4
and 6 of this Agreement.

 

    28

     

    

 

13.5
Statute of Limitations. The parties agree that all applicable statutes of limitation and time-based defenses (including,
but not limited to, estoppel and laches) shall be tolled while the procedures set forth in Sections 13.3(a) are pending. The parties
shall cooperate in taking any actions necessary to achieve this result.

 

14.
Miscellaneous.

 

14.1
Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement,
and shall be sent by hand, recognized national overnight courier, registered or certified mail, postage prepaid, in each case
return receipt requested or (except with respect to notice of termination) confirmed facsimile transmission or confirmed electronic
mail, to the following addresses or facsimile numbers of the parties:

 

		If to
                               M.I.T.:	Massachusetts
Institute of Technology

Technology
Licensing Office, Room NE18-501

255
Main Street, Kendall Square

Cambridge,
MA 02142-1601

Attention:
Director

Tel:
[***]

Fax:
[***]

 

    29

     

    

 

		If
                               to COMPANY:	MBcure
Ltd.

Science
Part, Ness Ziona

7403635,
Israel

Attention:
Chief Business Officer

Tel:
[***]

Fax:
[***]

 

If,
to COMPANY, notices regarding financial matters, including invoices:

 

Contact
Name: Sigal Fattal, CFO

Department:
Financial

Address:

Science
Part, Ness Ziona,

7403635,
Israel

Tel:
[***]

Fax:
[***]

Email:
[***]

 

All
notices under this Agreement shall be deemed effective upon receipt. A party may change its contact information immediately upon
written notice to the other party in the manner provided in this Section.

 

14.2
Governing Law. This Agreement and all disputes arising out of or related to this Agreement, or the performance, enforcement,
breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance
with the laws of the State of New York, U.S.A., without regard to conflict of laws principles, except that questions affecting
the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted.
The state and federal courts having jurisdiction over the City of New York, New York, USA, provide the exclusive forum for any
PATENT CHALLENGE and/or any court action between the parties relating to this Agreement. Each of the parties submits to the jurisdiction
of such courts and waives any claim that such court lacks jurisdiction over it or its AFFILIATES or constitutes an inconvenient
or improper forum.

 

    30

     

    

 

14.3
Confidentiality.

 

14.3.1  M.I.T.
shall keep confidential, not disclose to any third party and not use for any purpose other than monitoring COMPANY’s performance
under this Agreement all reports, notices, documents and information provided to M.I.T. by COMPANY under this Agreement; provided,
however, that M.I.T. may include in its annual reports totals derived from information received from COMPANY (without attribution
to COMPANY) that show revenues generated by the patents and patent applications licensed under this Agreement; and provided further
that the non-disclosure and non-use obligations shall not apply to any information that (a) is or becomes part of the public domain
other than by breach by M.I.T. of this Section 14.3.1, or (b) is required to be disclosed by M.I.T. pursuant to interrogatories,
requests for information or documents, subpoena, civil investigative demand issued by a court or governmental agency of competent
jurisdiction or as otherwise required by law (provided that, in such case, M.I.T. shall notify COMPANY promptly upon receipt thereof
and give COMPANY sufficient advance notice to permit it to seek a protective order or other similar order with respect to such
information). To the extent that it is reasonably necessary, M.I.T. may disclose information it is otherwise obligated under this
Section 14.3.1 not to disclose to (i) its employees and consultants on a need-to-know basis and on condition that such employees
abide by the obligations set forth in this Section 14.3.1 and (ii) in confidence, to lawyers, accountants and financial advisors.

 

14.3.2  Each
party shall keep the terms of this Agreement confidential and not disclose them to third parties other than in confidence to its
and its Affiliates’ employees and consultants without the prior consent of the other party, except that (a) COMPANY may
disclose this Agreement and/or the terms hereof in confidence to any bona fide prospective investor in or acquirer of COMPANY,
or any bona fide prospective purchaser or licensee of a business or technology to which this Agreement pertains, (b) COMPANY shall
have the right to disclose this Agreement as required by any securities laws or regulations or the regulations of any stock exchange,
and (c) each party may disclose the existence of the relationship created by this Agreement without the disclosure of any financial
details of this Agreement.

 

14.4
Force Majeure. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party,
including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially
reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable
dispatch whenever such causes are removed.

 

14.5
Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument
signed by both parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and
shall not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 

14.6
Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason,
such invalidity or unenforceability shall not affect any other provision of this Agreement, and the parties shall negotiate in
good faith to modify the Agreement to preserve (to the extent possible) their original intent. If the parties fail to reach a
modified agreement within [***] after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved
in accordance with the procedures set forth in Article 13. While the dispute is pending resolution, this Agreement shall be construed
as if such provision were deleted by agreement of the parties.

 

    31

     

    

 

14.7
Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their respective permitted
successors and assigns.

 

14.8
Headings. All headings are for convenience only and shall not affect the meaning of any provision of this Agreement.

 

14.9
Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to its subject matter
and supersedes all prior agreements or understandings between the parties relating to its subject matter.

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives.

 

The
EFFECTIVE DATE of this Agreement is 25th April 2017.

 

	MASSACHUSETTS
    INSTITUTE OF	 	MBCURE
    LTD.
	TECHNOLOGY 	 	 	 
	 	 	 	 	 
	By:	/s/
    Lesley Millar-Nicholson	 	By:	/s/
    Johnathan Solomon
	Name:	Lesley
    Millar-Nicholson	 	Name:  	Johnathan
    Solomon
	Title:	Director,
    Technology Licensing Office	 	Title:	CEO

 

	MASSACHUSETTS
    INSTITUTE OF	 
	TECHNOLOGY	 
	 	 	 
	By:	/s/
    Maria T. Zuber	 
	Name:
    	Maria
    T. Zuber	 
	Title:	Vice
    President for Research	 
	 	E.
    A. Griswold Professor of Geophysics	 

 

    32

     

    

 

APPENDIX
A

 

List
of Patent Applications and Patents

 

I.
United States Patents and Applications

 

[***]

 

II.
International (non-U.S.) Patents and Applications

 

 

 

 

 

 

 

 

 

    33

     

    

 

APPENDIX
B

 

List
of Countries (excluding United States) for which

PATENT
RIGHTS Applications Will Be Filed, Prosecuted and Maintained

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    34

     

    

 

EXHIBIT
A

 

CONFLICT
AVOIDANCE STATEMENT

 

	 	Name:	 	 
	 	 	 	 
	 	Dept. or
    Lab.:	 	 
	 	 	 	 
	 	Company:	 	 
	 	 	 	 
	 	Address:	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	Licensed Technology:	 	 

 

Because
of the M.I.T. license granted to the above company and my equity position with this company, I acknowledge the potential for a
possible conflict of interest between the performance of research at M.I.T. and my contractual or other obligations to this company.
Therefore, I will not:

 

		1)	use
                                         students at M.I.T. for research and development projects for the company;

 

		2)	restrict
                                         or delay access to information from my M.I.T. research;

 

		3)	take
                                         direct or indirect research support from the company in order to support my activities
                                         at M.I.T.; or

 

		4)	employ
                                         students at the company, except in accordance with Section 4.5.2, “Faculty and
                                         Students,” in the Policies and Procedures Guide.

 

In
addition, in order to avoid the appearance of a conflict, I will attempt to differentiate clearly between the intellectual directions
of my M.I.T. research and my contributions to the company. To that end, I will expressly inform my department head/laboratory
director annually of the general nature of my activities on behalf of the company.

 

	 	Signed:	 
	 	Date:	 

 

	Approved by:	 	 
	 	 	 
	Name (print):	 	 
	(Dept. Head or
    Lab Dir)	 

 

*
“Equity” includes stock, options, warrants or other financial instruments convertible into stock, which are directly
or indirectly controlled by the inventor.

 

 

35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]